"source","date","assertionType","evidenceType","exactText","modality","statementType","drug1Lab","drug1Type","drug1Role","dose1","drug2Lab","drug2Type","drug2Role","dose2","objectRegimens","objectFormulation","objectDuration","preciptRegimens","preciptFormulation","preciptDuration","numOfParticipants","auc","aucType","aucDirection","cl","clType","clDirection","cmax","cmaxType","cmaxDirection","t12","t12Type","t12Direction"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/70b079e2-a1f7-4a93-8685-d60a4d7c1280.html","2015-10-14 12:10:56 -0400","DDI-clinical-trial","evidence-supports","CYP 2D6 inhibitors: In healthy subjects, co-administration of pimozide 2 mg (single dose) and paroxetine 60 mg resulted in a 151% increase in pimozide AUC and a 62% increase in pimozide Cmax compared to pimozide administered alone. The increase in pimozide AUC and Cmax is related to the CYP 2D6 inhibitory properties of paroxetine. Concomitant use of pimozide and paroxetine or other strong CYP 2D6 inhibitors are contraindicated (see CONTRAINDICATIONS).","ncit:positive","ncit:quantitative","paroxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","60","pimozide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","2","SD","Oral","1","UNK","Oral","Unk","Unk","151","Percent","Increase","Unk","UNK","UNK","62","Percent","Increase","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/70b079e2-a1f7-4a93-8685-d60a4d7c1280.html","2015-10-14 12:07:40 -0400","DDI-clinical-trial","evidence-supports","Pimozide and Celexa: In a controlled study, a single dose of pimozide 2 mg coadministered with racemic citalopram 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone. Racemic citalopram did not alter the mean AUC or Cmax of pimozide. The mechanism of this pharmacodynamic interaction is not known. Concomitant use of Pimozide and Celexa or Lexapro is contraindicated (See CONTRAINDICATIONS).","ncit:negative","ncit:quantitative","citalopram","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","40","pimozide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","2","SD","Oral","1","Daily","Oral","11","Unk","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html","2015-10-14 11:57:06 -0400","drug-drug-interaction","evidence-supports","Rifampin has been reported to substantially decrease the plasma concentrations of the following antiviral drugs: atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir. These antiviral drugs must not be co-administered with rifampin. (See CONTRAINDICATIONS.) ","ncit:positive","ncit:Qualitative","Rifampin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"saquinavir","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b24028",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html","2015-10-14 11:57:06 -0400","drug-drug-interaction","evidence-supports","Rifampin has been reported to substantially decrease the plasma concentrations of the following antiviral drugs: atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir. These antiviral drugs must not be co-administered with rifampin. (See CONTRAINDICATIONS.) ","ncit:positive","ncit:Qualitative","Rifampin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"tipranavir","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b23786",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html","2015-10-14 11:57:06 -0400","drug-drug-interaction","evidence-supports","Rifampin has been reported to substantially decrease the plasma concentrations of the following antiviral drugs: atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir. These antiviral drugs must not be co-administered with rifampin. (See CONTRAINDICATIONS.) ","ncit:positive","ncit:Qualitative","Rifampin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"atazanavir","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b23874",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html","2015-10-14 11:57:06 -0400","drug-drug-interaction","evidence-supports","Rifampin has been reported to substantially decrease the plasma concentrations of the following antiviral drugs: atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir. These antiviral drugs must not be co-administered with rifampin. (See CONTRAINDICATIONS.) ","ncit:positive","ncit:Qualitative","fosamprenavir","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b23925","Rifampin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html","2015-10-14 11:57:06 -0400","drug-drug-interaction","evidence-supports","Rifampin has been reported to substantially decrease the plasma concentrations of the following antiviral drugs: atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir. These antiviral drugs must not be co-administered with rifampin. (See CONTRAINDICATIONS.) ","ncit:positive","ncit:Qualitative","antiviral drugs","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:object-drug-of-interaction","nodeID://b23952","Rifampin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html","2015-10-14 11:57:06 -0400","drug-drug-interaction","evidence-supports","Rifampin has been reported to substantially decrease the plasma concentrations of the following antiviral drugs: atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir. These antiviral drugs must not be co-administered with rifampin. (See CONTRAINDICATIONS.) ","ncit:positive","ncit:Qualitative","darunavir","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b24092","Rifampin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html","2015-10-13 12:06:23 -0400","drug-drug-interaction","evidence-supports","Concomitant administration of clarithromycin with cisapride, pimozide, astemizole, or terfenadine is contraindicated (see CONTRAINDICATIONS.)","ncit:positive","ncit:Qualitative","clarithromycin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"astemizole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b24009",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html","2015-10-13 12:06:23 -0400","drug-drug-interaction","evidence-supports","Concomitant administration of clarithromycin with cisapride, pimozide, astemizole, or terfenadine is contraindicated (see CONTRAINDICATIONS.)","ncit:positive","ncit:Qualitative","pimozide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b23940","clarithromycin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html","2015-10-13 12:06:23 -0400","drug-drug-interaction","evidence-supports","Concomitant administration of clarithromycin with cisapride, pimozide, astemizole, or terfenadine is contraindicated (see CONTRAINDICATIONS.)","ncit:positive","ncit:Qualitative","clarithromycin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"cisapride","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b23918",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html","2015-10-13 12:06:23 -0400","drug-drug-interaction","evidence-supports","Concomitant administration of clarithromycin with cisapride, pimozide, astemizole, or terfenadine is contraindicated (see CONTRAINDICATIONS.)","ncit:positive","ncit:Qualitative","terfenadine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b23654","clarithromycin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html","2015-10-13 12:06:23 -0400","drug-drug-interaction","evidence-supports","In addition, there have been reports of interactions of erythromycin or clarithromycin with drugs not thought to be metabolized by CYP3A, including hexobarbital, phenytoin, and valproate.","ncit:positive","ncit:Qualitative","phenytoin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b23987","clarithromycin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html","2015-10-13 12:06:23 -0400","drug-drug-interaction","evidence-supports","In addition, there have been reports of interactions of erythromycin or clarithromycin with drugs not thought to be metabolized by CYP3A, including hexobarbital, phenytoin, and valproate.","ncit:positive","ncit:Qualitative","hexobarbital","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b23709","clarithromycin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html","2015-10-13 12:06:23 -0400","drug-drug-interaction","evidence-supports","In addition, there have been reports of interactions of erythromycin or clarithromycin with drugs not thought to be metabolized by CYP3A, including hexobarbital, phenytoin, and valproate.","ncit:positive","ncit:Qualitative","valproate","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b23912","clarithromycin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html","2015-10-13 12:04:13 -0400","drug-drug-interaction","evidence-supports","There have been spontaneous or published reports of CYP3A based interactions of erythromycin and/or clarithromycin with cyclosporine, carbamazepine, tacrolimus, alfentanil, disopyramide, rifabutin, quinidine, methylprednisolone, cilostazol, and bromocriptine.","ncit:positive","ncit:Qualitative","clarithromycin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"carbamazepine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b24086",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html","2015-10-13 12:04:13 -0400","drug-drug-interaction","evidence-supports","There have been spontaneous or published reports of CYP3A based interactions of erythromycin and/or clarithromycin with cyclosporine, carbamazepine, tacrolimus, alfentanil, disopyramide, rifabutin, quinidine, methylprednisolone, cilostazol, and bromocriptine.","ncit:positive","ncit:Qualitative","bromocriptine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b24039","clarithromycin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html","2015-10-13 12:04:13 -0400","drug-drug-interaction","evidence-supports","There have been spontaneous or published reports of CYP3A based interactions of erythromycin and/or clarithromycin with cyclosporine, carbamazepine, tacrolimus, alfentanil, disopyramide, rifabutin, quinidine, methylprednisolone, cilostazol, and bromocriptine.","ncit:positive","ncit:Qualitative","quinidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b24023","clarithromycin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html","2015-10-13 12:04:13 -0400","drug-drug-interaction","evidence-supports","Sildenafil (Viagra) :Erythromycin has been reported to increase the systemic exposure (AUC) of sildenafil. A similar interaction may occur with clarithromycin; reduction of sildenafil dosage should be considered. (See Viagra package insert","ncit:positive","ncit:Qualitative","Sildenafil","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b24055","clarithromycin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html","2015-10-13 12:04:13 -0400","drug-drug-interaction","evidence-supports","There have been spontaneous or published reports of CYP3A based interactions of erythromycin and/or clarithromycin with cyclosporine, carbamazepine, tacrolimus, alfentanil, disopyramide, rifabutin, quinidine, methylprednisolone, cilostazol, and bromocriptine.","ncit:positive","ncit:Qualitative","disopyramide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b24049","clarithromycin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html","2015-10-13 12:04:13 -0400","drug-drug-interaction","evidence-supports","There have been spontaneous or published reports of CYP3A based interactions of erythromycin and/or clarithromycin with cyclosporine, carbamazepine, tacrolimus, alfentanil, disopyramide, rifabutin, quinidine, methylprednisolone, cilostazol, and bromocriptine.","ncit:positive","ncit:Qualitative","clarithromycin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"tacrolimus","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b23645",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html","2015-10-13 12:04:13 -0400","drug-drug-interaction","evidence-supports","There have been spontaneous or published reports of CYP3A based interactions of erythromycin and/or clarithromycin with cyclosporine, carbamazepine, tacrolimus, alfentanil, disopyramide, rifabutin, quinidine, methylprednisolone, cilostazol, and bromocriptine.","ncit:positive","ncit:Qualitative","clarithromycin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"alfentanil","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b23741",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html","2015-10-13 12:04:13 -0400","drug-drug-interaction","evidence-supports","There have been spontaneous or published reports of CYP3A based interactions of erythromycin and/or clarithromycin with cyclosporine, carbamazepine, tacrolimus, alfentanil, disopyramide, rifabutin, quinidine, methylprednisolone, cilostazol, and bromocriptine.","ncit:positive","ncit:Qualitative","methylprednisolone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b24056","clarithromycin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html","2015-10-13 12:04:13 -0400","drug-drug-interaction","evidence-supports","There have been spontaneous or published reports of CYP3A based interactions of erythromycin and/or clarithromycin with cyclosporine, carbamazepine, tacrolimus, alfentanil, disopyramide, rifabutin, quinidine, methylprednisolone, cilostazol, and bromocriptine.","ncit:positive","ncit:Qualitative","clarithromycin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"cilostazol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b23869",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html","2015-10-13 12:04:13 -0400","drug-drug-interaction","evidence-supports","There have been spontaneous or published reports of CYP3A based interactions of erythromycin and/or clarithromycin with cyclosporine, carbamazepine, tacrolimus, alfentanil, disopyramide, rifabutin, quinidine, methylprednisolone, cilostazol, and bromocriptine.","ncit:positive","ncit:Qualitative","rifabutin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b23858","clarithromycin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html","2015-10-13 12:04:13 -0400","drug-drug-interaction","evidence-supports","There have been spontaneous or published reports of CYP3A based interactions of erythromycin and/or clarithromycin with cyclosporine, carbamazepine, tacrolimus, alfentanil, disopyramide, rifabutin, quinidine, methylprednisolone, cilostazol, and bromocriptine.","ncit:positive","ncit:Qualitative","cyclosporine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b23579","clarithromycin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html","2015-10-13 11:59:07 -0400","drug-drug-interaction","evidence-supports","Spontaneous reports in the postmarketing period suggest that concomitant administration of clarithromycin and oral anticoagulants may potentiate the effects of the oral anticoagulants. Prothrombin times should be carefully monitored while patients are receiving clarithromycin and oral anticoagulants simultaneously.","ncit:positive","ncit:Qualitative","clarithromycin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"anticoagulants","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:object-drug-of-interaction","nodeID://b23701",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html","2015-10-13 11:59:07 -0400","drug-drug-interaction","evidence-supports","Colchicine is a substrate for both CYP3A and the efflux transporter, P-glycoprotein (Pgp). Clarithromycin and other macrolides are known to inhibit CYP3A and Pgp. When clarithromycin and colchicine are administered together, inhibition of Pgp and/or CYP3A by clarithromycin may lead to increased exposure to colchicine. Patients should be monitored for clinical symptoms of colchicine toxicity. (See WARNINGS.)","ncit:positive","ncit:Qualitative","clarithromycin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"colchicine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b24091",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html","2015-10-13 11:59:07 -0400","drug-drug-interaction","evidence-supports","Erythromycin and clarithromycin are substrates and inhibitors of the 3A isoform subfamily of the cytochrome P450 enzyme system (CYP3A). Coadministration of erythromycin or clarithromycin and a drug primarily metabolized by CYP3A may be associated with elevations in drug concentrations that could increase or prolong both the therapeutic and adverse effects of the concomitant drug. Dosage adjustment may be considered, and when possible, serum concentrations of drugs primarily metabolized by CYP3A should be monitored closely in patients concurrently receiving clarithromycin or erythromycin.","ncit:positive","ncit:Qualitative","clarithromycin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"erythromycin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b23996",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html","2015-10-13 11:59:07 -0400","drug-drug-interaction","evidence-supports","Elevated digoxin serum concentrations in patients receiving clarithromycin and digoxin concomitantly have also been reported in postmarketing surveillance. Some patients have shown clinical signs consistent with digoxin toxicity, including potentially fatal arrhythmias. Serum digoxin concentrations should be carefully monitored while patients are receiving digoxin and clarithromycin simultaneously.","ncit:positive","ncit:Qualitative","digoxin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b23902","clarithromycin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html","2015-10-13 11:56:52 -0400","DDI-clinical-trial","evidence-supports","Concomitant administration of clarithromycin and ritonavir (n=22) resulted in a 77% increase in clarithromycin AUC and a 100% decrease in the AUC of 14-OH clarithromycin. Clarithromycin may be administered without dosage adjustment to patients with normal renal function taking ritonavir. However, for patients with renal impairment, the following dosage adjustments should be considered. For patients with CLCR 30 to 60 mL/min, the dose of clarithromycin should be reduced by 50%. For patients with CLCR < 30 mL/min, the dose of clarithromycin should be decreased by 75%.","ncit:positive","ncit:quantitative","clarithromycin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","Unk","ritonavir","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","Unk","UNK","UNK","Unk","UNK","UNK","Unk","22","77","Percent","Increase","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html","2015-10-13 11:56:52 -0400","drug-drug-interaction","evidence-supports","Concomitant administration of fluconazole 200 mg daily and clarithromycin 500 mg twice daily to 21 healthy volunteers led to increases in the mean steady-state clarithromycin Cmin and AUC of 33% and 18%, respectively. Steady-state concentrations of 14-OH clarithromycin were not significantly affected by concomitant administration of fluconazole.","ncit:negative","ncit:Qualitative","fluconazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"14-OH clarithromycin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite","dikbD2R:object-drug-of-interaction","nodeID://b23753",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html","2015-10-13 11:56:52 -0400","DDI-clinical-trial","evidence-supports","Concomitant administration of clarithromycin and ritonavir (n=22) resulted in a 77% increase in clarithromycin AUC and a 100% decrease in the AUC of 14-OH clarithromycin. Clarithromycin may be administered without dosage adjustment to patients with normal renal function taking ritonavir. However, for patients with renal impairment, the following dosage adjustments should be considered. For patients with CLCR 30 to 60 mL/min, the dose of clarithromycin should be reduced by 50%. For patients with CLCR < 30 mL/min, the dose of clarithromycin should be decreased by 75%.","ncit:positive","ncit:quantitative","ritonavir","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","Unk","14-OH clarithromycin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite","dikbD2R:object-drug-of-interaction","Unk","UNK","UNK","Unk","UNK","UNK","Unk","22","100","Percent","Increase","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html","2015-10-13 11:52:38 -0400","DDI-clinical-trial","evidence-supports","Simultaneous oral administration of clarithromycin tablets and zidovudine to HIV infected adult patients resulted in decreased steady-state zidovudine concentrations. When 500 mg of clarithromycin were administered twice daily, steady-state zidovudine AUC was reduced by a mean of 12% (n=4). Individual values ranged from a decrease of 34% to an increase of 14%. Based on limited data in 24 patients, when clarithromycin tablets were administered two to four hours prior to oral zidovudine, the steady-state zidovudine Cmax was increased by approximately 2-fold, whereas the AUC was unaffected.","ncit:positive","ncit:quantitative","clarithromycin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","Unk","zidovudine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","Unk","UNK","Oral","Unk","UNK","Oral","Unk","24","No change","UNK","UNK","Unk","UNK","UNK","2","Fold","Increase","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html","2015-10-13 11:52:38 -0400","DDI-clinical-trial","evidence-supports","Concomitant administration of fluconazole 200 mg daily and clarithromycin 500 mg twice daily to 21 healthy volunteers led to increases in the mean steady-state clarithromycin Cmin and AUC of 33% and 18%, respectively. Steady-state concentrations of 14-OH clarithromycin were not significantly affected by concomitant administration of fluconazole.","ncit:positive","ncit:quantitative","clarithromycin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","500","fluconazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","200","BID","Oral","Unk","Daily","Oral","Unk","21","18","Percent","Increase","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html","2015-10-13 11:52:38 -0400","DDI-clinical-trial","evidence-supports","Clarithromycin 500 mg every 8 hours was given in combination with omeprazole 40 mg daily to healthy adult subjects. The steady-state plasma concentrations of omeprazole were increased (Cmax, AUC0-24, and T1/2 increases of 30%, 89%, and 34%, respectively), by the concomitant administration of clarithromycin. The mean 24-hour gastric pH value was 5.2 when omeprazole was administered alone and 5.7 when coadministered with clarithromycin.","ncit:positive","ncit:quantitative","Clarithromycin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","500","omeprazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","40","Q8","Oral","Unk","Q8","Oral","Unk","Unk","89","Percent","Increase","Unk","UNK","UNK","30","Percent","Increase","34","Percent","Increase"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html","2015-10-13 11:52:38 -0400","DDI-clinical-trial","evidence-supports","Simultaneous oral administration of clarithromycin tablets and zidovudine to HIV infected adult patients resulted in decreased steady-state zidovudine concentrations. When 500 mg of clarithromycin were administered twice daily, steady-state zidovudine AUC was reduced by a mean of 12% (n=4). Individual values ranged from a decrease of 34% to an increase of 14%. Based on limited data in 24 patients, when clarithromycin tablets were administered two to four hours prior to oral zidovudine, the steady-state zidovudine Cmax was increased by approximately 2-fold, whereas the AUC was unaffected.","ncit:positive","ncit:quantitative","clarithromycin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","500","zidovudine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","Unk","BID","Oral","Unk","BID","Oral","Unk","4","12","Percent","Increase","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html","2015-10-13 11:52:38 -0400","DDI-clinical-trial","evidence-supports","Simultaneous administration of clarithromycin tablets and didanosine to 12 HIV-infected adult patients resulted in no statistically significant change in didanosine pharmacokinetics.","ncit:negative","ncit:quantitative","didanosine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","Unk","clarithromycin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","Unk","UNK","UNK","Unk","UNK","UNK","Unk","12","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html","2015-10-13 11:52:38 -0400","DDI-clinical-trial","evidence-supports","Clarithromycin use in patients who are receiving theophylline may be associated with an increase of serum theophylline concentrations. Monitoring of serum theophylline concentrations should be considered for patients receiving high doses of theophylline or with baseline concentrations in the upper therapeutic range. In two studies in which theophylline was administered with clarithromycin (a theophylline sustained-release formulation was dosed at either 6.5 mg/kg or 12 mg/kg together with 250 or 500 mg ql2h clarithromycin), the steady-state levels of Cmax, Cmin, and the area under the serum concentration time curve (AUC) of theophylline increased about 20%.","ncit:positive","ncit:quantitative","theophylline","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","6.5 or 12 mg/kg","clarithromycin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","250 or 500","UNK","Oral","Unk","Q12","Oral","Unk","Unk","20","Percent","Increase","Unk","UNK","UNK","20","Percent","Increase","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html","2015-10-13 11:24:28 -0400","DDI-clinical-trial","evidence-supports","Clarithromycin 500 mg every 8 hours was given in combination with omeprazole 40 mg daily to healthy adult males. The plasma levels of clarithromycin and 14-hydroxy-clarithromycin were increased by the concomitant administration of omeprazole. For clarithromycin, the mean Cmax was 10% greater, the mean Cmin was 27% greater, and the mean AUC0-8 was 15% greater when clarithromycin was administered with omeprazole than when clarithromycin was administered alone. Similar results were seen for 14-hydroxy-clarithromycin, the mean Cmax was 45% greater, the mean Cmin was 57% greater, and the mean AUC0-8 was 45% greater. Clarithromycin concentrations in the gastric tissue and mucus were also increased by concomitant administration of omeprazole.","ncit:positive","ncit:quantitative","Clarithromycin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","500","omeprazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","40","Q8","Oral","Unk","Daily","Oral","Unk","Unk","15","Percent","Increase","Unk","UNK","UNK","10","Percent","Increase","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html","2015-10-13 11:24:28 -0400","DDI-clinical-trial","evidence-supports","Clarithromycin 500 mg every 8 hours was given in combination with omeprazole 40 mg daily to healthy adult males. The plasma levels of clarithromycin and 14-hydroxy-clarithromycin were increased by the concomitant administration of omeprazole. For clarithromycin, the mean Cmax was 10% greater, the mean Cmin was 27% greater, and the mean AUC0-8 was 15% greater when clarithromycin was administered with omeprazole than when clarithromycin was administered alone. Similar results were seen for 14-hydroxy-clarithromycin, the mean Cmax was 45% greater, the mean Cmin was 57% greater, and the mean AUC0-8 was 45% greater. Clarithromycin concentrations in the gastric tissue and mucus were also increased by concomitant administration of omeprazole.","ncit:positive","ncit:quantitative","omeprazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","40","14-hydroxy-clarithromycin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite","dikbD2R:object-drug-of-interaction","Unk","UNK","UNK","Unk","Daily","Oral","Unk","Unk","45","Percent","Increase","Unk","UNK","UNK","45","Percent","Increase","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c00d1607-ac36-457b-a34b-75ad74f9cf0a.html","2015-10-13 11:13:09 -0400","drug-drug-interaction","evidence-supports","The metabolism of saquinavir is mediated primarily by CYP3A. Additionally, saquinavir is a substrate for P-glycoprotein (P-gp). Therefore, drugs that affect CYP3A and/or P-gp may modify the pharmacokinetics of saquinavir. Coadministration with drugs that are potent inducers of CYP3A (e.g., phenobarbital, phenytoin, carbamazepine) may result in decreased plasma concentrations of saquinavir and reduced therapeutic effect.","ncit:positive","ncit:Qualitative","phenytoin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"saquinavir","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b24087",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c00d1607-ac36-457b-a34b-75ad74f9cf0a.html","2015-10-13 11:13:09 -0400","drug-drug-interaction","evidence-supports","The metabolism of saquinavir is mediated primarily by CYP3A. Additionally, saquinavir is a substrate for P-glycoprotein (P-gp). Therefore, drugs that affect CYP3A and/or P-gp may modify the pharmacokinetics of saquinavir. Coadministration with drugs that are potent inducers of CYP3A (e.g., phenobarbital, phenytoin, carbamazepine) may result in decreased plasma concentrations of saquinavir and reduced therapeutic effect.","ncit:positive","ncit:Qualitative","saquinavir","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b23691","phenobarbital","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c00d1607-ac36-457b-a34b-75ad74f9cf0a.html","2015-10-13 11:13:09 -0400","drug-drug-interaction","evidence-supports","The metabolism of saquinavir is mediated primarily by CYP3A. Additionally, saquinavir is a substrate for P-glycoprotein (P-gp). Therefore, drugs that affect CYP3A and/or P-gp may modify the pharmacokinetics of saquinavir. Coadministration with drugs that are potent inducers of CYP3A (e.g., phenobarbital, phenytoin, carbamazepine) may result in decreased plasma concentrations of saquinavir and reduced therapeutic effect.","ncit:positive","ncit:Qualitative","saquinavir","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b23704","carbamazepine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5d103551-978f-472a-9c62-51e6e4dea068.html","2015-10-09 13:39:25 -0400","DDI-clinical-trial","evidence-supports","Concomitant treatment with rabeprazole (20 mg daily) and ketoconazole in healthy subjects decreased the bioavailability of ketoconazole by 30% and increased the AUC and Cmax for digoxin by 19% and 29%, respectively. Therefore, patients may need to be monitored when such drugs are taken concomitantly with rabeprazole. Co-administration of rabeprazole and antacids produced no clinically relevant changes in plasma rabeprazole concentrations.","ncit:positive","ncit:quantitative","ketoconazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","Unk","rabeprazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","20","UNK","UNK","Unk","Daily","Oral","Unk","Unk","19","Percent","Increase","Unk","UNK","UNK","29","Percent","Increase","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c25f968b-7037-4f60-9a02-2189769b0cbf.html","2015-10-09 13:32:08 -0400","DDI-clinical-trial","evidence-supports","Hypoglycemic Drugs–In a placebo-controlled trial in normal volunteers, administration of sertraline for 22 days (including 200 mg/day for the final 13 days) caused a statistically significant 16% decrease from baseline in the clearance of tolbutamide following an intravenous 1000 mg dose. Sertraline administration did not noticeably change either the plasma protein binding or the apparent volume of distribution of tolbutamide, suggesting that the decreased clearance was due to a change in the metabolism of the drug. The clinical significance of this decrease in tolbutamide clearance is unknown.","ncit:positive","ncit:quantitative","tolbutamide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","1000","sertraline","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","200","SD","IV","1","Daily","Oral","22","Unk","Unk","UNK","UNK","16","Percent","Decrease","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c25f968b-7037-4f60-9a02-2189769b0cbf.html","2015-10-09 13:32:08 -0400","DDI-clinical-trial","evidence-supports","Digoxin–In a placebo-controlled trial in normal volunteers, administration of sertraline for 17 days (including 200 mg/day for the last 10 days) did not change serum digoxin levels or digoxin renal clearance.","ncit:negative","ncit:quantitative","sertraline","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","200","digoxin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","Unk","UNK","UNK","Unk","Daily","Oral","17","10","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c25f968b-7037-4f60-9a02-2189769b0cbf.html","2015-10-09 13:32:08 -0400","DDI-clinical-trial","evidence-supports","Drugs Metabolized by P450 3A4–In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions. The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride. These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance. Results of the interaction study with cisapride indicate that sertraline 200 mg (q.d.) induces the metabolism of cisapride (cisapride AUC and Cmax were reduced by about 35%).","ncit:positive","ncit:quantitative","cisapride","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","Unk","sertraline","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","200","UNK","UNK","Unk","QD","Oral","Unk","Unk","35","Percent","Decrease","Unk","UNK","UNK","35","Percent","Decrease","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c25f968b-7037-4f60-9a02-2189769b0cbf.html","2015-10-09 13:32:08 -0400","DDI-clinical-trial","evidence-supports","n a controlled study of a single dose (2 mg) of pimozide, 200 mg sertraline (q.d.) co-administration to steady state was associated with a mean increase in pimozide AUC and Cmax of about 40%, but was not associated with any changes in EKG. Since the highest recommended pimozide dose (10 mg) has not been evaluated in combination with sertraline, the effect on QT interval and PK parameters at doses higher than 2 mg at this time are not known. While the mechanism of this interaction is unknown, due to the narrow therapeutic index of pimozide and due to the interaction noted at a low dose of pimozide, concomitant administration of sertraline and pimozide should be contraindicated (see ","ncit:positive","ncit:quantitative","pimozide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","2","sertraline","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","200","SD","Oral","1","QD","Oral","Unk","Unk","40","Percent","Increase","Unk","UNK","UNK","40","Percent","Increase","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html","2015-10-09 13:18:59 -0400","DDI-clinical-trial","evidence-supports","In a controlled study of healthy volunteers, after paroxetine was titrated to 60 mg daily, coadministration of a single dose of 2 mg pimozide was associated with mean increases in pimozide AUC of 151% and Cmax of 62%, compared to pimozide administered alone. The increase in pimozide AUC and Cmax is due to the CYP2D6 inhibitory properties of paroxetine. Due to the narrow therapeutic index of pimozide and its known ability to prolong the QT interval, concomitant use of pimozide and paroxetine is contraindicated (see CONTRAINDICATIONS).","ncit:positive","ncit:quantitative","paroxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","60","pimozide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","2","SD","Oral","1","Daily","Oral","Unk","Unk","151","Percent","Increase","Unk","UNK","UNK","62","Percent","Increase","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html","2015-10-02 15:28:05 -0400","DDI-clinical-trial","evidence-supports","Ketoconazole    Seven-day treatment with ketoconazole (200 mg per day), a potent inhibitor of CYP3A4, did not affect the steady-state pharmacokinetics of selegiline in subjects who received EMSAM 6 mg per 24 hours for 7 days and no differences in the pharmacokinetics of ketoconazole were observed [see Drug Interactions (7.4) and (7.5)]. ","ncit:negative","ncit:quantitative","ketoconazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","6","selegiline","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","200","Daily",,"7","Daily","tablet","7","Unk","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html","2015-10-02 15:28:05 -0400","DDI-clinical-trial","evidence-supports","Ibuprofen    In subjects who had received EMSAM 6 mg per 24 hours for 11 days, combined administration with the CYP2C9 substrate ibuprofen (800 mg single dose) did not affect the pharmacokinetics of either selegiline or ibuprofen [see Drug Interactions (7.4) and (7.5)]. ","ncit:negative","ncit:quantitative","ibuprofen","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","800","EMSAM","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:object-drug-of-interaction","6","Daily",,"11","SD","tablet","1","Unk","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html","2015-10-02 15:28:05 -0400","DDI-clinical-trial","evidence-supports","Levothyroxine    In healthy subjects who had received EMSAM 6 mg per 24 hours for 10 days, single dose administration with levothyroxine (150 mcg) did not alter the pharmacokinetics of either selegiline or levothyroxine [see Drug Interactions (7.4) and (7.5)].","ncit:negative","ncit:quantitative","levothyroxine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","6","EMSAM","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:precipitant-drug-of-interaction","0.15","SD","tablet","1","Daily",,"10","Unk","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html","2015-10-02 15:28:05 -0400","DDI-clinical-trial","evidence-supports","Olanzapine    In subjects who had received EMSAM 6 mg per 24 hours for 10 days, co-administration with olanzapine, a substrate for CYP1A2, CYP2D6, and possibly CYP2A6, did not affect the pharmacokinetics of selegiline or olanzapine [see Drug Interactions (7.4) and (7.5)].","ncit:negative","ncit:quantitative","olanzapine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","6","EMSAM","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:precipitant-drug-of-interaction","Unk","UNK","UNK","Unk","Daily",,"10","Unk","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html","2015-10-02 15:28:05 -0400","DDI-clinical-trial","evidence-supports","Alprazolam    In subjects who had received EMSAM 6 mg per 24 hours for 7 days, co-administration with alprazolam (15 mg per day), a CYP3A4 and CYP3A5 substrate, did not affect the pharmacokinetics of alprazolam or selegiline [see Drug Interactions (7.4) and (7.5)]. ","ncit:negative","ncit:quantitative","EMSAM","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","15","alprazolam","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","6","Daily","tablet","7","Daily",,"7","Unk","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html","2015-10-02 15:28:05 -0400","DDI-clinical-trial","evidence-supports","Ibuprofen    In subjects who had received EMSAM 6 mg per 24 hours for 11 days, combined administration with the CYP2C9 substrate ibuprofen (800 mg single dose) did not affect the pharmacokinetics of either selegiline or ibuprofen [see Drug Interactions (7.4) and (7.5)]. ","ncit:negative","ncit:quantitative","EMSAM","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:precipitant-drug-of-interaction","800","ibuprofen","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","6","SD","tablet","1","Daily",,"11","Unk","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html","2015-10-02 15:28:05 -0400","DDI-clinical-trial","evidence-supports","Phenylpropanolamine (PPA)    In subjects who had received EMSAM 6 mg per 24 hours for 9 days, co-administration with PPA (25 mg every 4 hours for 24 hours) did not affect the pharmacokinetics of PPA. There was a higher incidence of significant blood pressure elevations with the co-administration of EMSAM and PPA than with PPA alone, suggesting a possible pharmacodynamic interaction [see Drug Interactions (7.4) and (7.5)]. ","ncit:negative","ncit:quantitative","EMSAM","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:precipitant-drug-of-interaction","25","PPA","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","6","UNK","tablet","Unk","Daily",,"9","Unk","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html","2015-10-02 15:20:43 -0400","DDI-clinical-trial","evidence-supports","Carbamazepine    Carbamazepine is an enzyme inducer and typically causes decreases in drug exposure; however, approximately 2-fold increased systemic exposure of selegiline and its metabolites, L-amphetamine and L-methamphetamine were seen after single application of EMSAM 6 mg per 24 hours in subjects who had received carbamazepine (400 mg per day) for 14 days. Changes in plasma selegiline concentrations were nearly 2-fold and variable across the subject population. Such increases may increase the risk of a hypertensive crisis when carbamazepine is used with EMSAM at any dose [see Contraindications (4), Warnings and Precautions (5.3) and Drug Interaction (7.4)].","ncit:positive","ncit:quantitative","carbamazepine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","Unk","L-methamphetamine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite","dikbD2R:object-drug-of-interaction","400","UNK","UNK","Unk","Daily","tablet","14","Unk","2","Fold","Increase","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html","2015-10-02 15:20:43 -0400","DDI-clinical-trial","evidence-supports","Carbamazepine    Carbamazepine is an enzyme inducer and typically causes decreases in drug exposure; however, approximately 2-fold increased systemic exposure of selegiline and its metabolites, L-amphetamine and L-methamphetamine were seen after single application of EMSAM 6 mg per 24 hours in subjects who had received carbamazepine (400 mg per day) for 14 days. Changes in plasma selegiline concentrations were nearly 2-fold and variable across the subject population. Such increases may increase the risk of a hypertensive crisis when carbamazepine is used with EMSAM at any dose [see Contraindications (4), Warnings and Precautions (5.3) and Drug Interaction (7.4)].","ncit:positive","ncit:quantitative","L-amphetamine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite","dikbD2R:object-drug-of-interaction","400","carbamazepine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","Unk","UNK","UNK","Unk","Daily","tablet","14","Unk","2","Fold","Increase","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/75bf3473-2d70-4d41-93cd-afa1015e45bb.html","2015-10-01 10:49:57 -0400","drug-drug-interaction","evidence-supports","In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).","ncit:positive","ncit:Qualitative","TCA","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:object-drug-of-interaction",,"phenothiazines","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/75bf3473-2d70-4d41-93cd-afa1015e45bb.html","2015-10-01 10:49:57 -0400","drug-drug-interaction","evidence-supports","In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).","ncit:positive","ncit:Qualitative","TCA","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:object-drug-of-interaction",,"sertraline","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/75bf3473-2d70-4d41-93cd-afa1015e45bb.html","2015-10-01 10:49:57 -0400","drug-drug-interaction","evidence-supports","The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decrease by concomitant administration with hepatic enzyme inducers (e.g., barbiturates, phenytoin), and adjustment of the dosage of imipramine may therefore be necessary.","ncit:positive","ncit:Qualitative","imipramine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,"phenytoin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/75bf3473-2d70-4d41-93cd-afa1015e45bb.html","2015-10-01 10:49:57 -0400","drug-drug-interaction","evidence-supports","In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).","ncit:positive","ncit:Qualitative","SSRIs","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:precipitant-drug-of-interaction",,"TCA","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/75bf3473-2d70-4d41-93cd-afa1015e45bb.html","2015-10-01 10:49:57 -0400","drug-drug-interaction","evidence-supports","The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decrease by concomitant administration with hepatic enzyme inducers (e.g., barbiturates, phenytoin), and adjustment of the dosage of imipramine may therefore be necessary.","ncit:positive","ncit:Qualitative","barbiturates","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:precipitant-drug-of-interaction",,"imipramine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/75bf3473-2d70-4d41-93cd-afa1015e45bb.html","2015-10-01 10:49:57 -0400","drug-drug-interaction","evidence-supports","The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decrease by concomitant administration with hepatic enzyme inducers (e.g., barbiturates, phenytoin), and adjustment of the dosage of imipramine may therefore be necessary.","ncit:positive","ncit:Qualitative","fluoxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"imipramine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/75bf3473-2d70-4d41-93cd-afa1015e45bb.html","2015-10-01 10:49:57 -0400","drug-drug-interaction","evidence-supports","In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).","ncit:positive","ncit:Qualitative","cimetidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"TCA","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/75bf3473-2d70-4d41-93cd-afa1015e45bb.html","2015-10-01 10:49:57 -0400","drug-drug-interaction","evidence-supports","In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary","ncit:positive","ncit:Qualitative","TCA","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:object-drug-of-interaction",,"flecainide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/75bf3473-2d70-4d41-93cd-afa1015e45bb.html","2015-10-01 10:49:57 -0400","drug-drug-interaction","evidence-supports","In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).","ncit:positive","ncit:Qualitative","TCA","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:object-drug-of-interaction",,"fluoxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/75bf3473-2d70-4d41-93cd-afa1015e45bb.html","2015-10-01 10:49:57 -0400","drug-drug-interaction","evidence-supports","In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).","ncit:positive","ncit:Qualitative","quinidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"TCA","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/75bf3473-2d70-4d41-93cd-afa1015e45bb.html","2015-10-01 10:49:57 -0400","drug-drug-interaction","evidence-supports","The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decrease by concomitant administration with hepatic enzyme inducers (e.g., barbiturates, phenytoin), and adjustment of the dosage of imipramine may therefore be necessary.","ncit:positive","ncit:Qualitative","imipramine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,"cimetidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/75bf3473-2d70-4d41-93cd-afa1015e45bb.html","2015-10-01 10:49:57 -0400","drug-drug-interaction","evidence-supports","In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).","ncit:positive","ncit:Qualitative","TCA","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:object-drug-of-interaction",,"propafenone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/75bf3473-2d70-4d41-93cd-afa1015e45bb.html","2015-10-01 10:49:57 -0400","drug-drug-interaction","evidence-supports","In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).","ncit:positive","ncit:Qualitative","TCA","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:object-drug-of-interaction",,"paroxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c66a11c1-3093-45ef-b348-3b196c05ba0c.html","2015-10-01 10:31:02 -0400","drug-drug-interaction","evidence-supports","In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dosage regimen of a TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).","ncit:positive","ncit:Qualitative","propafenone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"TCA","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c66a11c1-3093-45ef-b348-3b196c05ba0c.html","2015-10-01 10:31:02 -0400","drug-drug-interaction","evidence-supports","In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dosage regimen of a TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).","ncit:positive","ncit:Qualitative","TCA","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:object-drug-of-interaction",,"sertraline","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c66a11c1-3093-45ef-b348-3b196c05ba0c.html","2015-10-01 10:31:02 -0400","drug-drug-interaction","evidence-supports","In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dosage regimen of a TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).","ncit:positive","ncit:Qualitative","TCA","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:object-drug-of-interaction",,"SSRIs","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c66a11c1-3093-45ef-b348-3b196c05ba0c.html","2015-10-01 10:31:02 -0400","drug-drug-interaction","evidence-supports","In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dosage regimen of a TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).","ncit:positive","ncit:Qualitative","TCA","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:object-drug-of-interaction",,"cimetidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c66a11c1-3093-45ef-b348-3b196c05ba0c.html","2015-10-01 10:31:02 -0400","drug-drug-interaction","evidence-supports","In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dosage regimen of a TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).","ncit:positive","ncit:Qualitative","TCA","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:object-drug-of-interaction",,"phenothiazines","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c66a11c1-3093-45ef-b348-3b196c05ba0c.html","2015-10-01 10:31:02 -0400","drug-drug-interaction","evidence-supports","In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dosage regimen of a TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).","ncit:positive","ncit:Qualitative","TCA","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:object-drug-of-interaction",,"fluoxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c66a11c1-3093-45ef-b348-3b196c05ba0c.html","2015-10-01 10:31:02 -0400","drug-drug-interaction","evidence-supports","In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dosage regimen of a TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).","ncit:positive","ncit:Qualitative","TCA","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:object-drug-of-interaction",,"flecainide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c66a11c1-3093-45ef-b348-3b196c05ba0c.html","2015-10-01 10:31:02 -0400","drug-drug-interaction","evidence-supports","In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dosage regimen of a TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).","ncit:positive","ncit:Qualitative","paroxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"TCA","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c66a11c1-3093-45ef-b348-3b196c05ba0c.html","2015-10-01 10:31:02 -0400","drug-drug-interaction","evidence-supports","In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dosage regimen of a TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).","ncit:positive","ncit:Qualitative","TCA","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:object-drug-of-interaction",,"quinidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c3ca69e6-1ea0-4c2c-abcb-7264b2e79a87.html","2015-09-30 12:41:52 -0400","drug-drug-interaction","evidence-supports","Because of the pharmacologic similarity of maprotiline hydrochloride to the tricyclic antidepressants, the plasma concentration of maprotiline may be increased when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by concomitant administration with hepatic enzyme inducers (e.g., barbiturates, phenytoin), as has occurred with tricyclic antidepressants. Adjustment of the dosage of maprotiline hydrochloride may therefore be necessary in such cases.","ncit:positive","ncit:Qualitative","barbiturates","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:precipitant-drug-of-interaction",,"maprotiline","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c3ca69e6-1ea0-4c2c-abcb-7264b2e79a87.html","2015-09-30 12:41:52 -0400","drug-drug-interaction","evidence-supports","Because of the pharmacologic similarity of maprotiline hydrochloride to the tricyclic antidepressants, the plasma concentration of maprotiline may be increased when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by concomitant administration with hepatic enzyme inducers (e.g., barbiturates, phenytoin), as has occurred with tricyclic antidepressants. Adjustment of the dosage of maprotiline hydrochloride may therefore be necessary in such cases.","ncit:positive","ncit:Qualitative","fluoxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"maprotiline","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c3ca69e6-1ea0-4c2c-abcb-7264b2e79a87.html","2015-09-30 12:41:52 -0400","drug-drug-interaction","evidence-supports","Because of the pharmacologic similarity of maprotiline hydrochloride to the tricyclic antidepressants, the plasma concentration of maprotiline may be increased when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by concomitant administration with hepatic enzyme inducers (e.g., barbiturates, phenytoin), as has occurred with tricyclic antidepressants. Adjustment of the dosage of maprotiline hydrochloride may therefore be necessary in such cases.","ncit:positive","ncit:Qualitative","maprotiline","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,"phenytoin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c3ca69e6-1ea0-4c2c-abcb-7264b2e79a87.html","2015-09-30 12:41:52 -0400","drug-drug-interaction","evidence-supports","Because of the pharmacologic similarity of maprotiline hydrochloride to the tricyclic antidepressants, the plasma concentration of maprotiline may be increased when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by concomitant administration with hepatic enzyme inducers (e.g., barbiturates, phenytoin), as has occurred with tricyclic antidepressants. Adjustment of the dosage of maprotiline hydrochloride may therefore be necessary in such cases.","ncit:positive","ncit:Qualitative","cimetidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"maprotiline","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/16a4a314-f97e-4e91-95e9-576a3773d284.html","2015-09-30 10:48:18 -0400","DDI-clinical-trial","evidence-supports","Pregabalin-There were no clinically significant changes in the steady-state pharmacokinetics of milnacipran or pregabalin following twice a day co-administration of 50 mg milnacipran and 150 mg pregabalin. ","ncit:negative","ncit:quantitative","milnacipran","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","150","pregabalin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","50","BID","tablet","Unk","BID","tablet","Unk","Unk","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/16a4a314-f97e-4e91-95e9-576a3773d284.html","2015-09-30 10:48:18 -0400","DDI-clinical-trial","evidence-supports","Warfarin-Steady-state milnacipran (200 mg/day) did not affect the pharmacokinetics of R-warfarin and S-warfarin or the pharmacodynamics (as assessed by measurement of prothrombin INR) of a single dose of 25 mg warfarin. The pharmacokinetics of Savella were not altered by warfarin. ","ncit:negative","ncit:quantitative","Savella","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:object-drug-of-interaction","25","warfarin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","200","Daily","tablet","Unk","SD","tablet","1","Unk","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/16a4a314-f97e-4e91-95e9-576a3773d284.html","2015-09-30 10:48:18 -0400","DDI-clinical-trial","evidence-supports","Fluoxetine-Switching from fluoxetine (20 mg once a day), a strong inhibitor of CYP2D6 and a moderate inhibitor of CYP2C19, to milnacipran (100 mg/day) without a washout period did not affect the pharmacokinetics of milnacipran. ","ncit:negative","ncit:quantitative","milnacipran","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","20","fluoxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","100","Daily","tablet","Unk","Daily","tablet","Unk","Unk","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/16a4a314-f97e-4e91-95e9-576a3773d284.html","2015-09-30 10:48:18 -0400","DDI-clinical-trial","evidence-supports","Carbamazepine-There were no clinically significant changes in the pharmacokinetics of milnacipran following co-administration of Savella (100 mg/day) and carbamazepine (200 mg twice a day). No changes were observed in the pharmacokinetics of carbamazepine or its epoxide metabolite due to co-administration with Savella. ","ncit:negative","ncit:quantitative","milnacipran","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","200","carbamazepine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","100","Daily","tablet","Unk","BID","tablet","Unk","Unk","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/16a4a314-f97e-4e91-95e9-576a3773d284.html","2015-09-30 10:48:18 -0400","DDI-clinical-trial","evidence-supports","Lorazepam-There was no pharmacokinetic interaction between a single dose of Savella (50 mg) and lorazepam (1.5 mg). ","ncit:negative","ncit:quantitative","Savella","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:object-drug-of-interaction","1.5","lorazepam","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","50","SD","tablet","1","SD","tablet","1","Unk","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/16a4a314-f97e-4e91-95e9-576a3773d284.html","2015-09-30 10:48:18 -0400","DDI-clinical-trial","evidence-supports","Lorazepam-There was no pharmacokinetic interaction between a single dose of Savella (50 mg) and lorazepam (1.5 mg). ","ncit:negative","ncit:quantitative","lorazepam","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","50","Savella","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:precipitant-drug-of-interaction","1.5","SD","tablet","1","SD","tablet","1","Unk","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/16a4a314-f97e-4e91-95e9-576a3773d284.html","2015-09-30 10:48:18 -0400","DDI-clinical-trial","evidence-supports","Lithium-Multiple doses of Savella (100 mg/day) did not affect the pharmacokinetics of lithium. ","ncit:negative","ncit:quantitative","Savella","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:precipitant-drug-of-interaction","100","lithium","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","Unk","UNK","UNK","Unk","Daily","tablet","Unk","Unk","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/16a4a314-f97e-4e91-95e9-576a3773d284.html","2015-09-30 10:48:18 -0400","DDI-clinical-trial","evidence-supports","Digoxin-There was no pharmacokinetic interaction between Savella (200 mg/day) and digoxin    (0.2 mg/day Lanoxicaps) following multiple-dose administration to healthy subjects. ","ncit:negative","ncit:quantitative","Savella","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:precipitant-drug-of-interaction","200","digoxin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","0.2","Daily","tablet","Unk","Daily","tablet","Unk","Unk","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/16a4a314-f97e-4e91-95e9-576a3773d284.html","2015-09-30 10:48:18 -0400","DDI-clinical-trial","evidence-supports","Digoxin-There was no pharmacokinetic interaction between Savella (200 mg/day) and digoxin    (0.2 mg/day Lanoxicaps) following multiple-dose administration to healthy subjects. ","ncit:negative","ncit:quantitative","Savella","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:object-drug-of-interaction","0.2","digoxin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","200","Daily","tablet","Unk","Daily","tablet","Unk","Unk","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/16a4a314-f97e-4e91-95e9-576a3773d284.html","2015-09-30 10:48:18 -0400","DDI-clinical-trial","evidence-supports","Pregabalin-There were no clinically significant changes in the steady-state pharmacokinetics of milnacipran or pregabalin following twice a day co-administration of 50 mg milnacipran and 150 mg pregabalin. ","ncit:negative","ncit:quantitative","milnacipran","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","50","pregabalin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","150","BID","tablet","Unk","BID","tablet","Unk","Unk","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/16a4a314-f97e-4e91-95e9-576a3773d284.html","2015-09-30 10:48:18 -0400","DDI-clinical-trial","evidence-supports","Warfarin-Steady-state milnacipran (200 mg/day) did not affect the pharmacokinetics of R-warfarin and S-warfarin or the pharmacodynamics (as assessed by measurement of prothrombin INR) of a single dose of 25 mg warfarin. The pharmacokinetics of Savella were not altered by warfarin. ","ncit:negative","ncit:quantitative","warfarin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","200","milnacipran","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","25","SD","tablet","1","Daily","tablet","Unk","Unk","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/16a4a314-f97e-4e91-95e9-576a3773d284.html","2015-09-30 10:48:18 -0400","DDI-clinical-trial","evidence-supports","Clomipramine-Switching from clomipramine (75 mg once a day) to milnacipran (100 mg/day) without a washout period did not lead to clinically significant changes in the pharmacokinetics of milnacipran. Because an increase in adverse events (eg, euphoria and postural hypotension) was observed after switching from clomipramine to milnacipran, monitoring of patients during treatment switch is recommended. ","ncit:negative","ncit:quantitative","clomipramine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","100","milnacipran","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","75","Daily","tablet","Unk","Daily","tablet","Unk","Unk","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e.html","2015-09-29 11:41:50 -0400","drug-drug-interaction","evidence-supports","The plasma concentration of CMI has been reported to be increased by the concomitant administration of haloperidol; plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well. Administration of CMI has been reported to increase the plasma levels of phenobarbital, if given concomitantly (see CLINICAL PHARMACOLOGY, Interactions).","ncit:positive","ncit:Qualitative","CMI","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,"tricyclic antidepressants","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e.html","2015-09-29 11:41:50 -0400","drug-drug-interaction","evidence-supports","The plasma concentration of CMI has been reported to be increased by the concomitant administration of haloperidol; plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well. Administration of CMI has been reported to increase the plasma levels of phenobarbital, if given concomitantly (see CLINICAL PHARMACOLOGY, Interactions).","ncit:positive","ncit:Qualitative","phenytoin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"tricyclic antidepressants","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e.html","2015-09-29 11:41:50 -0400","drug-drug-interaction","evidence-supports"," Administration of CMI has been reported to increase the plasma levels of phenobarbital, if given concomitantly","ncit:positive","ncit:Qualitative","phenobarbital","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,"CMI","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html","2015-09-29 11:28:40 -0400","drug-drug-interaction","evidence-supports","In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type IC antiarrhythmics propafenone and flecainide). While all the SSRIs, e.g., fluoxetine, sertraline, paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).","ncit:positive","ncit:Qualitative","fluoxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"TCA","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html","2015-09-29 11:28:40 -0400","drug-drug-interaction","evidence-supports","In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type IC antiarrhythmics propafenone and flecainide). While all the SSRIs, e.g., fluoxetine, sertraline, paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).","ncit:positive","ncit:Qualitative","TCA","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:object-drug-of-interaction",,"propafenone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html","2015-09-29 11:28:40 -0400","drug-drug-interaction","evidence-supports","In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type IC antiarrhythmics propafenone and flecainide). While all the SSRIs, e.g., fluoxetine, sertraline, paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).","ncit:positive","ncit:Qualitative","TCA","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:object-drug-of-interaction",,"SSRIs","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html","2015-09-29 11:28:40 -0400","drug-drug-interaction","evidence-supports","In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type IC antiarrhythmics propafenone and flecainide). While all the SSRIs, e.g., fluoxetine, sertraline, paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).","ncit:positive","ncit:Qualitative","TCA","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:object-drug-of-interaction",,"flecainide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html","2015-09-29 11:28:40 -0400","drug-drug-interaction","evidence-supports","In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type IC antiarrhythmics propafenone and flecainide). While all the SSRIs, e.g., fluoxetine, sertraline, paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).","ncit:positive","ncit:Qualitative","TCA","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:object-drug-of-interaction",,"cimetidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html","2015-09-29 11:28:40 -0400","drug-drug-interaction","evidence-supports","Concurrent administration of cimetidine and tricyclic antidepressants can produce clinically significant increases in the plasma concentrations of the tricyclic antidepressants.","ncit:positive","ncit:Qualitative","cimetidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"tricyclic antidepressants","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html","2015-09-29 11:28:40 -0400","drug-drug-interaction","evidence-supports","In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type IC antiarrhythmics propafenone and flecainide). While all the SSRIs, e.g., fluoxetine, sertraline, paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).","ncit:positive","ncit:Qualitative","quinidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"TCA","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html","2015-09-29 11:28:40 -0400","drug-drug-interaction","evidence-supports","Certain drugs, particularly the psychostimulants and the phenothiazines, increase plasma levels of concomitantly administered tricyclic antidepressants through competition for the same metabolic enzyme systems. ","ncit:positive","ncit:Qualitative","psychostimulants","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:precipitant-drug-of-interaction",,"tricyclic antidepressants","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html","2015-09-29 11:28:40 -0400","drug-drug-interaction","evidence-supports","In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type IC antiarrhythmics propafenone and flecainide). While all the SSRIs, e.g., fluoxetine, sertraline, paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).","ncit:positive","ncit:Qualitative","TCA","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:object-drug-of-interaction",,"phenothiazines","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html","2015-09-29 11:28:40 -0400","drug-drug-interaction","evidence-supports","In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type IC antiarrhythmics propafenone and flecainide). While all the SSRIs, e.g., fluoxetine, sertraline, paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).","ncit:positive","ncit:Qualitative","sertraline","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"TCA","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html","2015-09-29 11:28:40 -0400","drug-drug-interaction","evidence-supports","In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type IC antiarrhythmics propafenone and flecainide). While all the SSRIs, e.g., fluoxetine, sertraline, paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).","ncit:positive","ncit:Qualitative","paroxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"TCA","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html","2015-09-29 11:28:40 -0400","drug-drug-interaction","evidence-supports","Other substances, particularly barbiturates and alcohol, induce liver enzyme activity and thereby reduce tricyclic antidepressant plasma levels. Similar effects have been reported with tobacco smoke.","ncit:positive","ncit:Qualitative","barbiturates","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:precipitant-drug-of-interaction",,"tricyclic antidepressant","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html","2015-09-29 11:28:40 -0400","drug-drug-interaction","evidence-supports","Certain drugs, particularly the psychostimulants and the phenothiazines, increase plasma levels of concomitantly administered tricyclic antidepressants through competition for the same metabolic enzyme systems.","ncit:positive","ncit:Qualitative","tricyclic antidepressants","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:object-drug-of-interaction",,"phenothiazines","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e.html","2015-09-29 09:58:27 -0400","drug-drug-interaction","evidence-supports","Co-administration of haloperidol with CMI increases plasma concentrations of CMI. ","ncit:positive","ncit:Qualitative","CMI","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,"haloperidol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e.html","2015-09-29 09:58:27 -0400","drug-drug-interaction","evidence-supports","The plasma concentration of CMI has been reported to be increased by the concomitant administration of haloperidol; plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well. Administration of CMI has been reported to increase the plasma levels of phenobarbital, if given concomitantly (see CLINICAL PHARMACOLOGY, Interactions).","ncit:positive","ncit:Qualitative","tricyclic antidepressants","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:object-drug-of-interaction",,"methylphenidate","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e.html","2015-09-29 09:58:27 -0400","drug-drug-interaction","evidence-supports","The plasma concentration of CMI has been reported to be increased by the concomitant administration of haloperidol; plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well. Administration of CMI has been reported to increase the plasma levels of phenobarbital, if given concomitantly (see CLINICAL PHARMACOLOGY, Interactions).","ncit:positive","ncit:Qualitative","haloperidol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"CMI","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e.html","2015-09-29 09:58:27 -0400","drug-drug-interaction","evidence-supports","Co-administration of CMI with phenobarbital increases plasma concentrations of phenobarbital ","ncit:positive","ncit:Qualitative","CMI","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"phenobarbital","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e.html","2015-09-29 09:58:27 -0400","drug-drug-interaction","evidence-supports","The plasma concentration of CMI has been reported to be increased by the concomitant administration of haloperidol; plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well. Administration of CMI has been reported to increase the plasma levels of phenobarbital, if given concomitantly (see CLINICAL PHARMACOLOGY, Interactions).","ncit:positive","ncit:Qualitative","hepatic enzyme inducers","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:precipitant-drug-of-interaction",,"tricyclic antidepressants","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e.html","2015-09-29 09:58:27 -0400","drug-drug-interaction","evidence-supports","The plasma concentration of CMI has been reported to be increased by the concomitant administration of haloperidol; plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well. Administration of CMI has been reported to increase the plasma levels of phenobarbital, if given concomitantly (see CLINICAL PHARMACOLOGY, Interactions).","ncit:positive","ncit:Qualitative","tricyclic antidepressants","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:object-drug-of-interaction",,"fluoxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e.html","2015-09-29 09:58:27 -0400","drug-drug-interaction","evidence-supports","The plasma concentration of CMI has been reported to be increased by the concomitant administration of haloperidol; plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well. Administration of CMI has been reported to increase the plasma levels of phenobarbital, if given concomitantly (see CLINICAL PHARMACOLOGY, Interactions).","ncit:positive","ncit:Qualitative","hepatic enzyme inhibitors","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:precipitant-drug-of-interaction",,"tricyclic antidepressants","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e.html","2015-09-29 09:58:27 -0400","drug-drug-interaction","evidence-supports","The plasma concentration of CMI has been reported to be increased by the concomitant administration of haloperidol; plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well. Administration of CMI has been reported to increase the plasma levels of phenobarbital, if given concomitantly (see CLINICAL PHARMACOLOGY, Interactions).","ncit:positive","ncit:Qualitative","barbiturates","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:precipitant-drug-of-interaction",,"tricyclic antidepressants","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a16297df-3158-48db-85e5-5cd506885556.html","2015-09-29 09:27:10 -0400","drug-drug-interaction","evidence-supports","In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine, cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).","ncit:positive","ncit:Qualitative","TCA","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:object-drug-of-interaction",,"quinidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a16297df-3158-48db-85e5-5cd506885556.html","2015-09-29 09:27:10 -0400","drug-drug-interaction","evidence-supports","In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine, cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).","ncit:positive","ncit:Qualitative","TCA","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:object-drug-of-interaction",,"sertraline","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a16297df-3158-48db-85e5-5cd506885556.html","2015-09-29 09:27:10 -0400","drug-drug-interaction","evidence-supports","In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine, cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).","ncit:positive","ncit:Qualitative","TCA","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:object-drug-of-interaction",,"fluoxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a16297df-3158-48db-85e5-5cd506885556.html","2015-09-29 09:27:10 -0400","drug-drug-interaction","evidence-supports","In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine, cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).","ncit:positive","ncit:Qualitative","phenothiazines","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:precipitant-drug-of-interaction",,"TCA","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a16297df-3158-48db-85e5-5cd506885556.html","2015-09-29 09:27:10 -0400","drug-drug-interaction","evidence-supports","In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine, cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).","ncit:positive","ncit:Qualitative","cimetidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"TCA","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a16297df-3158-48db-85e5-5cd506885556.html","2015-09-29 09:27:10 -0400","drug-drug-interaction","evidence-supports","In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine, cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).","ncit:positive","ncit:Qualitative","TCA","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:object-drug-of-interaction",,"selective serotonin reuptake inhibitors","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a16297df-3158-48db-85e5-5cd506885556.html","2015-09-29 09:27:10 -0400","drug-drug-interaction","evidence-supports","In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine, cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).","ncit:positive","ncit:Qualitative","flecainide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"TCA","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a16297df-3158-48db-85e5-5cd506885556.html","2015-09-29 09:27:10 -0400","drug-drug-interaction","evidence-supports","In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine, cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).","ncit:positive","ncit:Qualitative","propafenone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"TCA","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a16297df-3158-48db-85e5-5cd506885556.html","2015-09-29 09:27:10 -0400","drug-drug-interaction","evidence-supports","In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine, cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).","ncit:positive","ncit:Qualitative","paroxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"TCA","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ea35caf8-c8c8-481a-97a2-25f68cbc240b.html","2015-09-29 09:04:36 -0400","drug-drug-interaction","evidence-supports","In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the coadministration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).","ncit:positive","ncit:Qualitative","TCA","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:object-drug-of-interaction",,"selective serotonin reuptake inhibitors","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ea35caf8-c8c8-481a-97a2-25f68cbc240b.html","2015-09-29 09:04:36 -0400","drug-drug-interaction","evidence-supports","In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the coadministration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).","ncit:positive","ncit:Qualitative","TCA","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:object-drug-of-interaction",,"propafenone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ea35caf8-c8c8-481a-97a2-25f68cbc240b.html","2015-09-29 09:04:36 -0400","drug-drug-interaction","evidence-supports","In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the coadministration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).","ncit:positive","ncit:Qualitative","TCA","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:object-drug-of-interaction",,"sertraline","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ea35caf8-c8c8-481a-97a2-25f68cbc240b.html","2015-09-29 09:04:36 -0400","drug-drug-interaction","evidence-supports","In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the coadministration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).","ncit:positive","ncit:Qualitative","phenothiazines","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:precipitant-drug-of-interaction",,"TCA","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ea35caf8-c8c8-481a-97a2-25f68cbc240b.html","2015-09-29 09:04:36 -0400","drug-drug-interaction","evidence-supports","In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the coadministration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).","ncit:positive","ncit:Qualitative","TCA","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:object-drug-of-interaction",,"cimetidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ea35caf8-c8c8-481a-97a2-25f68cbc240b.html","2015-09-29 09:04:36 -0400","drug-drug-interaction","evidence-supports","In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the coadministration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).","ncit:positive","ncit:Qualitative","paroxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"TCA","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ea35caf8-c8c8-481a-97a2-25f68cbc240b.html","2015-09-29 09:04:36 -0400","drug-drug-interaction","evidence-supports","In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the coadministration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).","ncit:positive","ncit:Qualitative","TCA","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:object-drug-of-interaction",,"quinidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ea35caf8-c8c8-481a-97a2-25f68cbc240b.html","2015-09-29 09:04:36 -0400","drug-drug-interaction","evidence-supports","In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the coadministration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).","ncit:positive","ncit:Qualitative","TCA","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:object-drug-of-interaction",,"fluoxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ea35caf8-c8c8-481a-97a2-25f68cbc240b.html","2015-09-29 09:04:36 -0400","drug-drug-interaction","evidence-supports","In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the coadministration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).","ncit:positive","ncit:Qualitative","TCA","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:object-drug-of-interaction",,"flecainide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/010f9162-9f7f-4b6d-a6e4-4f832f26f38e.html","2015-09-25 10:47:09 -0400","DDI-clinical-trial","evidence-supports","In healthy male patients (n=24), carbamazepine (400 mg b.i.d.) increased mirtazapine (15 mg b.i.d.) clearance about 2-fold, resulting in a decrease in average plasma mirtazapine concentrations of 60%.    When phenytoin, carbamazepine, or another inducer of hepatic metabolism (such as rifampicin) is added to mirtazapine therapy, the mirtazapine dose may have to be increased. If treatment with such a medicinal product is discontinued, it may be necessary to reduce the mirtazapine dose.","ncit:positive","ncit:quantitative","mirtazapine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","400","carbamazepine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","15","BID","tablet","Unk","BID","tablet","Unk","24","Unk","UNK","UNK","2","Fold","Increase","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/010f9162-9f7f-4b6d-a6e4-4f832f26f38e.html","2015-09-25 10:47:09 -0400","DDI-clinical-trial","evidence-supports","Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. However, the impairment of motor skills produced by REMERON has been shown to be additive with those caused by diazepam. Accordingly, patients should be advised to avoid diazepam and other similar drugs while taking REMERON.","ncit:negative","ncit:quantitative","mirtazapine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","15","diazepam","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","15","UNK","tablet","Unk","UNK","tablet","Unk","12","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/010f9162-9f7f-4b6d-a6e4-4f832f26f38e.html","2015-09-25 10:47:09 -0400","DDI-clinical-trial","evidence-supports","In an in vivo interaction study in healthy, CYP2D6 extensive metabolizer patients (n=24), mirtazapine (30 mg/day), at steady state, did not cause relevant changes in the pharmacokinetics of steady state paroxetine (40 mg/day), a CYP2D6 inhibitor.","ncit:negative","ncit:quantitative","mirtazapine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","40","paroxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","30","Daily","tablet","Unk","Daily","tablet","Unk","24","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/010f9162-9f7f-4b6d-a6e4-4f832f26f38e.html","2015-09-25 10:47:09 -0400","DDI-clinical-trial","evidence-supports","In healthy, male, Caucasian patients (n=24), coadministration of the potent CYP3A4 inhibitor ketoconazole (200 mg b.i.d. for 6.5 days) increased the peak plasma levels and the AUC of a single 30-mg dose of mirtazapine by approximately 40% and 50%, respectively.    Caution should be exercised when coadministering mirtazapine with potent CYP3A4 inhibitors, HIV protease inhibitors, azole antifungals, erythromycin, or nefazodone.","ncit:positive","ncit:quantitative","ketoconazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","30","mirtazapine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","200","SD","tablet","1","BID","tablet","6.5","24","50","Percent","Increase","Unk","UNK","UNK","40","Percent","Increase","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/010f9162-9f7f-4b6d-a6e4-4f832f26f38e.html","2015-09-25 10:47:09 -0400","DDI-clinical-trial","evidence-supports","In an in vivo, nonrandomized, interaction study, subjects (n=6) in need of treatment with an antipsychotic and antidepressant drug, showed that mirtazapine (30 mg daily) at steady state did not influence the pharmacokinetics of risperidone (up to 3 mg b.i.d.).","ncit:negative","ncit:quantitative","risperidone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","30","mirtazapine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","3","BID","tablet","Unk","Daily","tablet","Unk","6","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/010f9162-9f7f-4b6d-a6e4-4f832f26f38e.html","2015-09-25 10:47:09 -0400","DDI-clinical-trial","evidence-supports","In healthy male patients (n=12), when cimetidine, a weak inhibitor of CYP1A2, CYP2D6, and CYP3A4, given at 800 mg b.i.d. at steady state was coadministered with mirtazapine (30 mg daily) at steady state, the Area Under the Curve (AUC) of mirtazapine increased more than 50%. Mirtazapine did not cause relevant changes in the pharmacokinetics of cimetidine. The mirtazapine dose may have to be decreased when concomitant treatment with cimetidine is started, or increased when cimetidine treatment is discontinued.","ncit:positive","ncit:quantitative","mirtazapine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","800","cimetidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","30","Daily","tablet","Unk","BID","tablet","Unk","12","50","Percent","Increase","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/010f9162-9f7f-4b6d-a6e4-4f832f26f38e.html","2015-09-25 10:47:09 -0400","DDI-clinical-trial","evidence-supports","In healthy male patients (n=12), when cimetidine, a weak inhibitor of CYP1A2, CYP2D6, and CYP3A4, given at 800 mg b.i.d. at steady state was coadministered with mirtazapine (30 mg daily) at steady state, the Area Under the Curve (AUC) of mirtazapine increased more than 50%. Mirtazapine did not cause relevant changes in the pharmacokinetics of cimetidine. The mirtazapine dose may have to be decreased when concomitant treatment with cimetidine is started, or increased when cimetidine treatment is discontinued.","ncit:negative","ncit:quantitative","Mirtazapine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","800","cimetidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","30","BID","tablet","Unk","Daily","tablet","Unk","12","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/010f9162-9f7f-4b6d-a6e4-4f832f26f38e.html","2015-09-25 10:47:09 -0400","DDI-clinical-trial","evidence-supports","In healthy male patients (n=18), phenytoin (200 mg daily) increased mirtazapine (30 mg daily) clearance about 2-fold, resulting in a decrease in average plasma mirtazapine concentrations of 45%. Mirtazapine did not significantly affect the pharmacokinetics of phenytoin.","ncit:negative","ncit:quantitative","mirtazapine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","200","phenytoin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","30","Daily","tablet","Unk","Daily","tablet","Unk","18","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/010f9162-9f7f-4b6d-a6e4-4f832f26f38e.html","2015-09-25 10:47:09 -0400","DDI-clinical-trial","evidence-supports","In healthy male patients (n=18), phenytoin (200 mg daily) increased mirtazapine (30 mg daily) clearance about 2-fold, resulting in a decrease in average plasma mirtazapine concentrations of 45%. Mirtazapine did not significantly affect the pharmacokinetics of phenytoin.","ncit:positive","ncit:quantitative","mirtazapine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","200","phenytoin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","30","Daily","tablet","Unk","Daily","tablet","Unk","18","Unk","UNK","UNK","2","Fold","Increase","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/010f9162-9f7f-4b6d-a6e4-4f832f26f38e.html","2015-09-25 10:47:09 -0400","DDI-clinical-trial","evidence-supports","No relevant clinical effects or significant changes in pharmacokinetics have been observed in healthy male subjects on concurrent treatment with subtherapeutic levels of lithium (600 mg/day for 10 days) at steady state and a single 30-mg dose of mirtazapine. The effects of higher doses of lithium on the pharmacokinetics of mirtazapine are unknown.","ncit:negative","ncit:quantitative","lithium","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","30","mirtazapine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","600","SD","tablet","1","Daily","tablet","10","Unk","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/010f9162-9f7f-4b6d-a6e4-4f832f26f38e.html","2015-09-25 10:47:09 -0400","DDI-clinical-trial","evidence-supports","In healthy, CYP2D6 extensive metabolizer patients (n=32), amitriptyline (75 mg daily), at steady state, did not cause relevant changes in the pharmacokinetics of steady state mirtazapine (30 mg daily); mirtazapine also did not cause relevant changes to the pharmacokinetics of amitriptyline.","ncit:negative","ncit:quantitative","amitriptyline","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","30","mirtazapine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","75","Daily","tablet","Unk","Daily","tablet","Unk","32","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/010f9162-9f7f-4b6d-a6e4-4f832f26f38e.html","2015-09-25 10:47:09 -0400","DDI-clinical-trial","evidence-supports","In healthy, CYP2D6 extensive metabolizer patients (n=32), amitriptyline (75 mg daily), at steady state, did not cause relevant changes in the pharmacokinetics of steady state mirtazapine (30 mg daily); mirtazapine also did not cause relevant changes to the pharmacokinetics of amitriptyline.","ncit:negative","ncit:quantitative","amitriptyline","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","30","mirtazapine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","75","Daily","tablet","Unk","Daily","tablet","Unk","32","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/f371258d-91b3-4b6a-ac99-434a1964c3af.html","2015-09-25 10:05:58 -0400","drug-drug-interaction","evidence-supports","No dose adjustment of FETZIMA is needed when co-administered with a CYP3A4 inducer or substrate. In vivo studies showed no clinically meaningful change in levomilnacipran exposure when co-administered with the CYP3A4 inducer carbamazepine or the CYP3A4 substrate alprazolam (see Figure 1). ","ncit:negative","ncit:Qualitative","carbamazepine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"levomilnacipran","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/f371258d-91b3-4b6a-ac99-434a1964c3af.html","2015-09-25 10:05:58 -0400","drug-drug-interaction","evidence-supports","Dose adjustment is recommended when FETZIMA is co-administered with strong inhibitors of CYP3A4 (e.g. ketoconazole) [see Dosage and Administration (2.7)]. An in vivo study showed a clinically meaningful increase in levomilnacipran exposure when FETZIMA was co-administered with the CYP3A4 inhibitor ketoconazole (see Figure 1). ","ncit:positive","ncit:Qualitative","ketoconazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"levomilnacipran","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/f371258d-91b3-4b6a-ac99-434a1964c3af.html","2015-09-25 10:05:58 -0400","drug-drug-interaction","evidence-supports","No dose adjustment of FETZIMA is needed when co-administered with a CYP3A4 inducer or substrate. In vivo studies showed no clinically meaningful change in levomilnacipran exposure when co-administered with the CYP3A4 inducer carbamazepine or the CYP3A4 substrate alprazolam (see Figure 1). ","ncit:negative","ncit:Qualitative","levomilnacipran","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,"alprazolam","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/829a4f51-c882-4b64-81f3-abfb03a52ebe.html","2015-09-24 15:55:00 -0400","DDI-clinical-trial","evidence-supports","Under steady-state conditions for duloxetine (20 mg qhs) and temazepam (30 mg qhs), the pharmacokinetics of duloxetine were not affected by co-administration. ","ncit:negative","ncit:quantitative","duloxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","30","temazepam","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","20","UNK","tablet","Unk","UNK","tablet","Unk","Unk","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/829a4f51-c882-4b64-81f3-abfb03a52ebe.html","2015-09-24 15:55:00 -0400","DDI-clinical-trial","evidence-supports","Duloxetine is a moderate inhibitor of CYP2D6. When duloxetine was administered (at a dose of 60 mg twice daily) in conjunction with a single 50 mg dose of desipramine, a CYP2D6 substrate, the AUC of desipramine increased 3-fold [see WARNINGS AND PRECAUTIONS (5.12)]. ","ncit:positive","ncit:quantitative","desipramine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","60","duloxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","50","UNK","tablet","1","BID","tablet","Unk","Unk","3","Fold","Increase","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/829a4f51-c882-4b64-81f3-abfb03a52ebe.html","2015-09-24 15:55:00 -0400","DDI-clinical-trial","evidence-supports","In vitro drug interaction studies demonstrate that duloxetine does not induce CYP1A2 activity. Therefore, an increase in the metabolism of CYP1A2 substrates (e.g., theophylline, caffeine) resulting from induction is not anticipated, although clinical studies of induction have not been performed. Duloxetine is an inhibitor of the CYP1A2 isoform in in vitro studies, and in two clinical studies the average (90% confidence interval) increase in theophylline AUC was 7% (1% to 15%) and 20% (13% to 27%) when co-administered with duloxetine (60 mg twice daily). ","ncit:positive","ncit:quantitative","theophylline","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","Unk","duloxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","60","BID","tablet","Unk","UNK","UNK","Unk","Unk","7-20","Percent","Increase","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/829a4f51-c882-4b64-81f3-abfb03a52ebe.html","2015-09-24 15:55:00 -0400","DDI-clinical-trial","evidence-supports","Concomitant administration of duloxetine 40 mg twice daily with fluvoxamine 100 mg, a potent CYP1A2 inhibitor, to CYP2D6 poor metabolizer subjects (n=14) resulted in a 6-fold increase in duloxetine AUC and Cmax.","ncit:positive","ncit:quantitative","fluvoxamine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","40","duloxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","100","BID","tablet","Unk","UNK","tablet","Unk","Unk","6","Fold","Increase","Unk","UNK","UNK","6","Fold","Increase","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/829a4f51-c882-4b64-81f3-abfb03a52ebe.html","2015-09-24 15:55:00 -0400","DDI-clinical-trial","evidence-supports","Serotonin release by platelets plays an important role in hemostasis. Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding. Altered anticoagulant effects, including increased bleeding, have been reported when SSRIs or SNRIs are co-administered with warfarin. Concomitant administration of warfarin (2 to 9 mg once daily) under steady state conditions with duloxetine 60 or 120 mg once daily for up to 14 days in healthy subjects (n=15) did not significantly change INR from baseline (mean INR changes ranged from 0.05 to +0.07). The total warfarin (protein bound plus free drug) pharmacokinetics (AUCτ,ss, Cmax,ss or tmax,ss) for both R- and S-warfarin were not altered by duloxetine. Because of the potential effect of duloxetine on platelets, patients receiving warfarin therapy should be carefully monitored when duloxetine is initiated or discontinued [see WARNINGS AND PRECAUTIONS (5.5)]. ","ncit:negative","ncit:quantitative","duloxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","60 or 120","warfarin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","Unk","UNK","UNK","Unk","Daily","tablet","14","15","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/829a4f51-c882-4b64-81f3-abfb03a52ebe.html","2015-09-24 15:55:00 -0400","DDI-clinical-trial","evidence-supports","Results of in vitro studies demonstrate that duloxetine does not inhibit activity. In a clinical study, the pharmacokinetics of S-warfarin, a CYP2C9 substrate, were not significantly affected by duloxetine [see DRUG INTERACTIONS (7.4)]. ","ncit:negative","ncit:quantitative","warfarin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","Unk","duloxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","Unk","UNK","UNK","Unk","UNK","UNK","Unk","Unk","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/829a4f51-c882-4b64-81f3-abfb03a52ebe.html","2015-09-24 15:55:00 -0400","DDI-clinical-trial","evidence-supports","Under steady-state conditions for duloxetine (60 mg Q 12 hours) and lorazepam (2 mg Q 12 hours), the pharmacokinetics of duloxetine were not affected by co-administration. ","ncit:negative","ncit:quantitative","duloxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","2","lorazepam","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","60","Q12","tablet","Unk","Q12","tablet","Unk","Unk","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/829a4f51-c882-4b64-81f3-abfb03a52ebe.html","2015-09-24 15:47:22 -0400","DDI-clinical-trial","evidence-supports","When duloxetine 60 mg was co-administered with fluvoxamine 100 mg, a potent CYP1A2 inhibitor, to male subjects (n=14) duloxetine AUC was increased approximately 6-fold, the Cmax was increased about 2.5-fold, and duloxetine t1/2 was increased approximately 3-fold. Other drugs that inhibit CYP1A2 metabolism include cimetidine and quinolone antimicrobials such as ciprofloxacin and enoxacin [see WARNINGS AND PRECAUTIONS (5.12)]. ","ncit:positive","ncit:quantitative","duloxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","100","fluvoxamine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","60","UNK","tablet","Unk","UNK","tablet","Unk","14","6","Fold","Increase","Unk","UNK","UNK","2.5","Fold","Increase","3","Fold","Increase"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/829a4f51-c882-4b64-81f3-abfb03a52ebe.html","2015-09-24 15:47:22 -0400","DDI-clinical-trial","evidence-supports","Concomitant use of duloxetine (40 mg once daily) with paroxetine (20 mg once daily) increased the concentration of duloxetine AUC by about 60%, and greater degrees of inhibition are expected with higher doses of paroxetine. Similar effects would be expected with other potent CYP2D6 inhibitors (e.g., fluoxetine, quinidine) [see WARNINGS AND PRECAUTIONS (5.12)]. ","ncit:positive","ncit:quantitative","duloxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","20","paroxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","40","Daily","tablet","Unk","Daily","tablet","Unk","Unk","50","Percent","Increase","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35.html","2015-09-24 15:38:09 -0400","DDI-clinical-trial","evidence-supports","In vitro studies showed minimal inhibitory effect of desvenlafaxine on CYP2D6. Clinical studies have shown that desvenlafaxine does not have a clinically relevant effect on CYP2D6 metabolism at the dose of 100 mg daily. When desvenlafaxine succinate was administered at a dose of 100 mg daily in conjunction with a single 50 mg dose of desipramine, a CYP2D6 substrate, the Cmax and AUC of desipramine increased approximately 25% and 17%, respectively. When 400 mg (8 times the recommended 50 mg dose) was administered, the Cmax and AUC of desipramine increased approximately 50% and 90%, respectively. Concomitant use of desvenlafaxine with a drug metabolized by CYP2D6 can result in higher concentrations of that drug [see Drug Interactions (7.5)].","ncit:positive","ncit:quantitative","desvenlafaxine succinate","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","50","desipramine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","100","SD","tablet","1","Daily","tablet","Unk","Unk","17","Percent","Increase","Unk","UNK","UNK","25","Percent","Increase","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35.html","2015-09-24 15:38:09 -0400","DDI-clinical-trial","evidence-supports","CYP3A4 is a minor pathway for the metabolism of desvenlafaxine. In a clinical study, ketoconazole (200 mg BID) increased the area under the concentration vs. time curve (AUC) of desvenlafaxine (400 mg single dose) by about 43% and Cmax by about 8%. Concomitant use of desvenlafaxine with potent inhibitors of CYP3A4 may result in higher concentrations of desvenlafaxine. ","ncit:positive","ncit:quantitative","desvenlafaxine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","200","ketoconazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","400","SD","tablet","1","BID","tablet","Unk","Unk","43","Percent","Increase","Unk","UNK","UNK","8","Percent","Increase","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35.html","2015-09-24 15:38:09 -0400","DDI-clinical-trial","evidence-supports","In vitro, desvenlafaxine does not inhibit or induce the CYP3A4 isozyme. In a clinical study, desvenlafaxine 400 mg daily (8 times the recommended 50 mg dose) was co-administered with a single 4 mg dose of midazolam (a CYP3A4 substrate). The AUC and Cmax of midazolam decreased by approximately 31% and 16%, respectively. Concomitant use of desvenlafaxine with a drug metabolized by CYP3A4 can result in lower exposures to that drug. ","ncit:positive","ncit:quantitative","desvenlafaxine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","4","midazolam","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","400","SD","tablet","1","Daily","tablet","Unk","Unk","31","Percent","Decrease","Unk","UNK","UNK","16","Percent","Decrease","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35.html","2015-09-24 15:38:09 -0400","DDI-clinical-trial","evidence-supports","In vitro studies showed minimal inhibitory effect of desvenlafaxine on CYP2D6. Clinical studies have shown that desvenlafaxine does not have a clinically relevant effect on CYP2D6 metabolism at the dose of 100 mg daily. When desvenlafaxine succinate was administered at a dose of 100 mg daily in conjunction with a single 50 mg dose of desipramine, a CYP2D6 substrate, the Cmax and AUC of desipramine increased approximately 25% and 17%, respectively. When 400 mg (8 times the recommended 50 mg dose) was administered, the Cmax and AUC of desipramine increased approximately 50% and 90%, respectively. Concomitant use of desvenlafaxine with a drug metabolized by CYP2D6 can result in higher concentrations of that drug [see Drug Interactions (7.5)].","ncit:positive","ncit:quantitative","desvenlafaxine succinate","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","400","desipramine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","100","SD","tablet","1","Daily","tablet","Unk","Unk","90","Percent","Increase","Unk","UNK","UNK","50","Percent","Increase","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35.html","2015-09-24 15:28:55 -0400","DDI-clinical-trial","evidence-supports","Clinical studies have shown that desvenlafaxine (100 mg daily) does not have a clinically relevant effect on tamoxifen and aripiprazole, compounds that are metabolized by a combination of both CYP2D6 and CYP3A4 enzymes (Figure 2).","ncit:negative","ncit:quantitative","aripiprazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","100","desvenlafaxine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","Unk","UNK","UNK","Unk","UNK","tablet","Unk","Unk","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35.html","2015-09-24 15:28:24 -0400","DDI-clinical-trial","evidence-supports","Clinical studies have shown that desvenlafaxine (100 mg daily) does not have a clinically relevant effect on tamoxifen and aripiprazole, compounds that are metabolized by a combination of both CYP2D6 and CYP3A4 enzymes (Figure 2).","ncit:negative","ncit:quantitative","tamoxifen","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","100","desvenlafaxine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","Unk","UNK","UNK","Unk","Daily","tablet","Unk","Unk","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c25f968b-7037-4f60-9a02-2189769b0cbf.html","2015-09-16 15:31:12 -0400","drug-drug-interaction","evidence-supports","Drugs Metabolized by P450 3A4–In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions. The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride. These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance. Results of the interaction study with cisapride indicate that sertraline 200 mg (q.d.) induces the metabolism of cisapride (cisapride AUC and Cmax were reduced by about 35%).","ncit:negative","ncit:Qualitative","sertraline","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"carbamazepine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b23687",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c25f968b-7037-4f60-9a02-2189769b0cbf.html","2015-09-16 15:31:12 -0400","DDI-clinical-trial","evidence-supports","Cimetidine–In a study assessing disposition of sertraline (100 mg) on the second of 8 days of cimetidine administration (800 mg daily), there were significant increases in sertraline mean AUC (50%), Cmax (24%) and half-life (26%) compared to the placebo group. The clinical significance of these changes is unknown.","ncit:positive","ncit:quantitative","sertraline","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","100","cimetidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","800","SD","Oral","2","Daily","Oral","8","Unk","50","Percent","Increase","Unk","UNK","UNK","24","Percent","Increase","26","Percent","Increase"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c25f968b-7037-4f60-9a02-2189769b0cbf.html","2015-09-16 15:31:12 -0400","drug-drug-interaction","evidence-supports","Drugs Metabolized by P450 3A4–In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions. The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride. These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance. Results of the interaction study with cisapride indicate that sertraline 200 mg (q.d.) induces the metabolism of cisapride (cisapride AUC and Cmax were reduced by about 35%).","ncit:negative","ncit:Qualitative","terfenadine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b24054","sertraline","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c25f968b-7037-4f60-9a02-2189769b0cbf.html","2015-09-16 15:31:12 -0400","drug-drug-interaction","evidence-supports","In a placebo-controlled trial in normal volunteers, the administration of two doses of sertraline did not significantly alter steady-state lithium levels or the renal clearance of lithium.","ncit:negative","ncit:Qualitative","lithium","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b24093","sertraline","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c25f968b-7037-4f60-9a02-2189769b0cbf.html","2015-09-16 15:31:12 -0400","DDI-clinical-trial","evidence-supports","In a study comparing the disposition of intravenously administered diazepam before and after 21 days of dosing with either sertraline (50 to 200 mg/day escalating dose) or placebo, there was a 32% decrease relative to baseline in diazepam clearance for the sertraline group compared to a 19% decrease relative to baseline for the placebo group (p < 0.03). There was a 23% increase in Tmax for desmethyldiazepam in the sertraline group compared to a 20% decrease in the placebo group (p < 0.03). The clinical significance of these changes is unknown.","ncit:positive","ncit:quantitative","diazepam","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","Unk","sertraline","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","50-200","UNK","IV","Unk","Daily","Oral","21","Unk","Unk","UNK","UNK","32","Percent","Decrease","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html","2015-09-14 11:32:07 -0400","drug-drug-interaction","evidence-supports","Coadministration of fosamprenavir/ritonavir with paroxetine significantly decreased plasma levels of paroxetine. Any dose adjustment should be guided by clinical effect (tolerability and efficacy).","ncit:positive","ncit:Qualitative","paroxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,"ritonavir","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","nodeID://b24067",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html","2015-09-14 11:32:07 -0400","drug-drug-interaction","evidence-supports","Coadministration of fosamprenavir/ritonavir with paroxetine significantly decreased plasma levels of paroxetine. Any dose adjustment should be guided by clinical effect (tolerability and efficacy)","ncit:positive","ncit:Qualitative","fosamprenavir","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","nodeID://b23862","paroxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html","2015-09-14 11:31:14 -0400","DDI-clinical-trial","evidence-supports","Daily oral dosing of paroxetine (30 mg once daily) increased steady-state AUC0-24, Cmax, and Cmin values of procyclidine (5 mg oral once daily) by 35%, 37%, and 67%, respectively, compared to procyclidine alone at steady state. If anticholinergic effects are seen, the dose of procyclidine should be reduced.","ncit:positive","ncit:quantitative","procyclidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","5","paroxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","30","Daily","Oral","Unk","Daily","Oral","Unk","Unk","35","Percent","Increase","Unk","UNK","UNK","37","Percent","Increase","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html","2015-09-14 11:31:14 -0400","DDI-clinical-trial","evidence-supports","In a study where propranolol (80 mg twice daily) was dosed orally for 18 days, the established steady-state plasma concentrations of propranolol were unaltered during coadministration with paroxetine (30 mg once daily) for the final 10 days. The effects of propranolol on paroxetine have not been evaluated (see ADVERSE REACTIONS: Postmarketing Reports).","ncit:negative","ncit:quantitative","propranolol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","80","paroxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","30","BID","Oral","18","Daily","Oral","10","Unk","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html","2015-09-14 11:31:14 -0400","drug-drug-interaction","evidence-supports","Under steady-state conditions, diazepam does not appear to affect paroxetine kinetics. The effects of paroxetine on diazepam were not evaluated.","ncit:negative","ncit:Qualitative","diazepam","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b23814","paroxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html","2015-09-14 11:21:10 -0400","DDI-clinical-trial","evidence-supports","Concomitant use of paroxetine with risperidone, a CYP2D6 substrate has also been evaluated. In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.","ncit:positive","ncit:quantitative","risperidone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","4-8","paroxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","20","Daily","Oral","Unk","Daily","Oral","Unk","Unk","4","Fold","Increase","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html","2015-09-14 11:21:10 -0400","drug-drug-interaction","evidence-supports","A multiple-dose study has shown that there is no pharmacokinetic interaction between paroxetine and lithium carbonate. However, due to the potential for serotonin syndrome, caution is advised when paroxetine is coadministered with lithium.","ncit:negative","ncit:Qualitative","lithium carbonate","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b24080","paroxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html","2015-09-14 11:21:10 -0400","DDI-clinical-trial","evidence-supports","The steady-state pharmacokinetics of paroxetine was not altered when administered with digoxin at steady state. Mean digoxin AUC at steady state decreased by 15% in the presence of paroxetine. Since there is little clinical experience, the concurrent administration of paroxetine and digoxin should be undertaken with caution.","ncit:positive","ncit:quantitative","paroxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","Unk","digoxin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","Unk","UNK","UNK","Unk","UNK","UNK","Unk","Unk","15","Percent","Decrease","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html","2015-09-14 11:21:10 -0400","DDI-clinical-trial","evidence-supports","The effect of paroxetine on the pharmacokinetics of atomoxetine has been evaluated when both drugs were at steady state. In healthy volunteers who were extensive metabolizers of CYP2D6, paroxetine 20 mg daily was given in combination with 20 mg atomoxetine every 12 hours. This resulted in increases in steady state atomoxetine AUC values that were 6- to 8-fold greater and in atomoxetine Cmax values that were 3- to 4-fold greater than when atomoxetine was given alone. Dosage adjustment of atomoxetine may be necessary and it is recommended that atomoxetine be initiated at a reduced dose when it is given with paroxetine.","ncit:positive","ncit:quantitative","atomoxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","20","paroxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","20","Q12","Oral","Unk","Daily","Oral","Unk","Unk","6-8","Fold","Increase","Unk","UNK","UNK","3-4","Fold","Increase","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html","2015-09-14 11:21:10 -0400","DDI-clinical-trial","evidence-supports","When a single oral 30 mg dose of paroxetine was administered at phenytoin steady state (300 mg once daily for 14 days), paroxetine AUC and T½ were reduced (by an average of 50% and 35%, respectively) compared to paroxetine administered alone. In a separate study, when a single oral 300 mg dose of phenytoin was administered at paroxetine steady state (30 mg once daily for 14 days), phenytoin AUC was slightly reduced (12% on average) compared to phenytoin administered alone. Since both drugs exhibit nonlinear pharmacokinetics, the above studies may not address the case where the 2 drugs are both being chronically dosed. No initial dosage adjustments are considered necessary when these drugs are coadministered; any subsequent adjustments should be guided by clinical effect (see ADVERSE REACTIONS: Postmarketing Reports).","ncit:positive","ncit:quantitative","phenytoin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","300","paroxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","30","SD","Oral","1","Daily","Oral","14","Unk","12","Percent","Decrease","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html","2015-09-14 11:21:10 -0400","drug-drug-interaction","evidence-supports","An in vivo interaction study involving the coadministration under steady-state conditions of paroxetine and terfenadine, a substrate for cytochrome CYP3A4, revealed no effect of paroxetine on terfenadine pharmacokinetics.","ncit:negative","ncit:Qualitative","paroxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"terfenadine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b24043",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html","2015-09-14 11:21:10 -0400","DDI-clinical-trial","evidence-supports","Many drugs, including most drugs effective in the treatment of major depressive disorder (paroxetine, other SSRIs and many tricyclics), are metabolized by the cytochrome P450 isozyme CYP2D6. Like other agents that are metabolized by CYP2D6, paroxetine may significantly inhibit the activity of this isozyme. In most patients (>90%), this CYP2D6 isozyme is saturated early during dosing with paroxetine. In 1 study, daily dosing of paroxetine (20 mg once daily) under steady-state conditions increased single dose desipramine (100 mg) Cmax, AUC, and T½ by an average of approximately 2-, 5-, and 3-fold, respectively. ","ncit:positive","ncit:quantitative","paroxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","20","desipramine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","100","SD","Oral","Unk","Daily","Oral","Unk","Unk","5","Fold","Increase","Unk","UNK","UNK","2","Fold","Increase","3","Fold","Increase"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html","2015-09-14 11:21:10 -0400","DDI-clinical-trial","evidence-supports","Concomitant use of paroxetine with risperidone, a CYP2D6 substrate has also been evaluated. In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.","ncit:positive","ncit:quantitative","9-hydroxyrisperidone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite","dikbD2R:object-drug-of-interaction","4-8","paroxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","20","Daily","Oral","Unk","Daily","Oral","Unk","Unk","10","Percent","Decrease","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html","2015-09-14 11:03:10 -0400","DDI-clinical-trial","evidence-supports","Phenobarbital induces many cytochrome P450 (oxidative) enzymes. When a single oral 30 mg dose of paroxetine was administered at phenobarbital steady state (100 mg once daily for 14 days), paroxetine AUC and T½ were reduced (by an average of 25% and 38%, respectively) compared to paroxetine administered alone. The effect of paroxetine on phenobarbital pharmacokinetics was not studied. Since paroxetine exhibits nonlinear pharmacokinetics, the results of this study may not address the case where the 2 drugs are both being chronically dosed. No initial dosage adjustment of paroxetine is considered necessary when coadministered with phenobarbital; any subsequent adjustment should be guided by clinical effect.","ncit:positive","ncit:quantitative","phenobarbital","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","100","paroxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","30","SD","Oral","1","Daily","Oral","14","Unk","25","Percent","Decrease","Unk","UNK","UNK","Unk","UNK","UNK","38","Percent","Decrease"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html","2015-09-14 11:03:10 -0400","DDI-clinical-trial","evidence-supports","When a single oral 30 mg dose of paroxetine was administered at phenytoin steady state (300 mg once daily for 14 days), paroxetine AUC and T½ were reduced (by an average of 50% and 35%, respectively) compared to paroxetine administered alone. In a separate study, when a single oral 300 mg dose of phenytoin was administered at paroxetine steady state (30 mg once daily for 14 days), phenytoin AUC was slightly reduced (12% on average) compared to phenytoin administered alone. Since both drugs exhibit nonlinear pharmacokinetics, the above studies may not address the case where the 2 drugs are both being chronically dosed. No initial dosage adjustments are considered necessary when these drugs are coadministered; any subsequent adjustments should be guided by clinical effect (see ADVERSE REACTIONS: Postmarketing Reports).","ncit:positive","ncit:quantitative","paroxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","30","phenytoin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","300","SD","Oral","1","Daily","Oral","14","Unk","50","Percent","Decrease","Unk","UNK","UNK","Unk","UNK","UNK","35","Percent","Decrease"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html","2015-09-14 11:00:37 -0400","DDI-clinical-trial","evidence-supports","Cimetidine inhibits many cytochrome P450 (oxidative) enzymes. In a study where paroxetine (30 mg once daily) was dosed orally for 4 weeks, steady-state plasma concentrations of paroxetine were increased by approximately 50% during coadministration with oral cimetidine (300 mg three times daily) for the final week. Therefore, when these drugs are administered concurrently, dosage adjustment of paroxetine after the 20 mg starting dose should be guided by clinical effect. The effect of paroxetine on cimetidine’s pharmacokinetics was not studied.","ncit:positive","ncit:quantitative","paroxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","30","cimetidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","300","Daily","Oral","28","TID","Oral","7","Unk","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html","2015-09-14 10:25:07 -0400","drug-drug-interaction","evidence-supports","In vitro drug interaction studies reveal that paroxetine inhibits CYP2D6. Clinical drug interaction studies have been performed with substrates of CYP2D6 and show that paroxetine can inhibit the metabolism of drugs metabolized by CYP2D6 including desipramine, risperidone, and atomoxetine (see PRECAUTIONS: Drug Interactions)","ncit:positive","ncit:Qualitative","paroxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"atomoxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b23947",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html","2015-09-14 10:25:07 -0400","drug-drug-interaction","evidence-supports","In vitro drug interaction studies reveal that paroxetine inhibits CYP2D6. Clinical drug interaction studies have been performed with substrates of CYP2D6 and show that paroxetine can inhibit the metabolism of drugs metabolized by CYP2D6 including desipramine, risperidone, and atomoxetine (see PRECAUTIONS: Drug Interactions).","ncit:positive","ncit:Qualitative","desipramine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b23963","paroxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html","2015-09-14 10:25:07 -0400","drug-drug-interaction","evidence-supports","In vitro drug interaction studies reveal that paroxetine inhibits CYP2D6. Clinical drug interaction studies have been performed with substrates of CYP2D6 and show that paroxetine can inhibit the metabolism of drugs metabolized by CYP2D6 including desipramine, risperidone, and atomoxetine (see PRECAUTIONS: Drug Interactions).","ncit:positive","ncit:Qualitative","risperidone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b23860","paroxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html","2015-09-10 15:01:13 -0400","drug-drug-interaction","evidence-supports","Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine. Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.","ncit:positive","ncit:Qualitative","imipramine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,"fluvoxamine maleate","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html","2015-09-10 15:01:13 -0400","DDI-clinical-trial","evidence-supports","A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction. On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone. ","ncit:negative","ncit:quantitative","fluvoxamine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","4","lorazepam","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","50","BID","Oral","Unk","SD","Oral","1","12","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html","2015-09-10 15:01:13 -0400","DDI-clinical-trial","evidence-supports","Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol. Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion. ","ncit:negative","ncit:quantitative","atenolol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","100","fluvoxamine maleate","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","100","Daily","Oral","Unk","Daily","Oral","Unk","6","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html","2015-09-10 15:01:13 -0400","DDI-clinical-trial","evidence-supports","Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean 5-fold increase (range 2 to 17) in minimum propranolol plasma concentrations. In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure. ","ncit:positive","ncit:quantitative","fluvoxamine maleate","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","160","propranolol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","100","Daily","Oral","Unk","Daily","Oral","Unk","Unk","Unk","UNK","UNK","Unk","UNK","UNK","5","Fold","Increase","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html","2015-09-10 15:01:13 -0400","drug-drug-interaction","evidence-supports","Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine. Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced. ","ncit:positive","ncit:Qualitative","amitriptyline","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,"fluvoxamine maleate","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html","2015-09-10 15:01:13 -0400","DDI-clinical-trial","evidence-supports","In a study of 13 healthy, male volunteers, a single 40 mg dose of tacrine added to fluvoxamine 100 mg/day administered at steady-state was associated with 5- and 8-fold increases in tacrine Cmax and AUC, respectively, compared to the administration of tacrine alone. Five subjects experienced nausea, vomiting, sweating, and diarrhea following coadministration, consistent with the cholinergic effects of tacrine. ","ncit:positive","ncit:quantitative","fluvoxamine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","40","tacrine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","100","SD","Oral","1","Daily","Oral","Unk","13","8","Fold","Increase","Unk","UNK","UNK","5","Fold","Increase","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html","2015-09-10 15:01:13 -0400","DDI-clinical-trial","evidence-supports","Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin. ","ncit:positive","ncit:quantitative","digoxin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","100","fluvoxamine maleate","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","1.25","SD","IV","1","Daily","Oral","18","8","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html","2015-09-10 15:01:13 -0400","DDI-clinical-trial","evidence-supports","A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction. On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone. ","ncit:negative","ncit:quantitative","lorazepam","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","4","fluvoxamine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","50","SD","Oral","1","BID","Oral","Unk","12","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html","2015-09-10 15:01:13 -0400","drug-drug-interaction","evidence-supports","Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine. Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced. ","ncit:positive","ncit:Qualitative","clomipramine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,"fluvoxamine maleate","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html","2015-09-03 16:19:40 -0400","DDI-clinical-trial","evidence-supports","Levothyroxine    In healthy subjects who had received EMSAM 6 mg per 24 hours for 10 days, single dose administration with levothyroxine (150 mcg) did not alter the pharmacokinetics of either selegiline or levothyroxine [see Drug Interactions (7.4) and (7.5)].","ncit:negative","ncit:quantitative","levothyroxine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","0.15","EMSAM","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:object-drug-of-interaction","6","Daily","Oral","10","SD","Oral","1","Unk","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html","2015-09-03 16:19:40 -0400","DDI-clinical-trial","evidence-supports","Ketoconazole    Seven-day treatment with ketoconazole (200 mg per day), a potent inhibitor of CYP3A4, did not affect the steady-state pharmacokinetics of selegiline in subjects who received EMSAM 6 mg per 24 hours for 7 days and no differences in the pharmacokinetics of ketoconazole were observed [see Drug Interactions (7.4) and (7.5)]. ","ncit:negative","ncit:quantitative","selegiline","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","6","ketoconazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","200","Daily","Oral","7","Daily","Oral","7","Unk","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html","2015-09-03 16:19:40 -0400","DDI-clinical-trial","evidence-supports","Risperidone    In subjects who had received EMSAM 6 mg per 24 hours for 10 days, co-administration with risperidone (2 mg per day for 7 days), a substrate for CYP2D6, did not affect the pharmacokinetics of selegiline or risperidone [see Drug Interactions (7.4) and (7.5)].","ncit:negative","ncit:quantitative","EMSAM","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:object-drug-of-interaction","6","risperidone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","2","Daily","Oral","10","Daily","Oral","7","Unk","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html","2015-09-03 16:19:40 -0400","DDI-clinical-trial","evidence-supports","Risperidone    In subjects who had received EMSAM 6 mg per 24 hours for 10 days, co-administration with risperidone (2 mg per day for 7 days), a substrate for CYP2D6, did not affect the pharmacokinetics of selegiline or risperidone [see Drug Interactions (7.4) and (7.5)].    Warfarin","ncit:negative","ncit:quantitative","EMSAM","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:precipitant-drug-of-interaction","6","risperidone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","2","Daily","Oral","7","Daily","Oral","10","Unk","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html","2015-09-03 16:19:40 -0400","DDI-clinical-trial","evidence-supports","Olanzapine    In subjects who had received EMSAM 6 mg per 24 hours for 10 days, co-administration with olanzapine, a substrate for CYP1A2, CYP2D6, and possibly CYP2A6, did not affect the pharmacokinetics of selegiline or olanzapine [see Drug Interactions (7.4) and (7.5)].","ncit:negative","ncit:quantitative","EMSAM","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:object-drug-of-interaction","6","olanzapine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","Unk","Daily","Oral","10","UNK","UNK","Unk","Unk","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html","2015-09-03 16:19:40 -0400","DDI-clinical-trial","evidence-supports","Pseudoephedrine    EMSAM 6 mg per 24 hours for 10 days, co-administered with pseudoephedrine (60 mg, 3 times a day) did not affect the pharmacokinetics of pseudoephedrine. There were no clinically significant changes in blood pressure during pseudoephedrine administration alone, or in combination with EMSAM [see Drug Interactions (7.4) and (7.5)]. ","ncit:negative","ncit:quantitative","pseudoephedrine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","60","EMSAM","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:precipitant-drug-of-interaction","6","TID","Oral","Unk","Daily","Oral","10","Unk","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html","2015-09-03 16:19:40 -0400","DDI-clinical-trial","evidence-supports","Warfarin    Warfarin is a substrate for CYP2C9 and CYP3A4 metabolism pathways. In healthy volunteers titrated with Coumadin®# (warfarin sodium) to clinical levels of anticoagulation (INR of 1.5 to 2), co-administration with EMSAM 6 mg per 24 hours for 7 days did not affect the pharmacokinetics of the individual warfarin enantiomers. EMSAM did not alter the clinical pharmacodynamic effects of warfarin as measured by INR, Factor VII or Factor X levels [see Drug Interactions (7.4) and (7.5)].","ncit:negative","ncit:quantitative","EMSAM","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:precipitant-drug-of-interaction","6","warfarin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","Unk","UNK","UNK","Unk","Daily","Oral","7","Unk","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html","2015-09-03 15:51:47 -0400","DDI-clinical-trial","evidence-supports","Carbamazepine    Carbamazepine is an enzyme inducer and typically causes decreases in drug exposure; however, approximately 2-fold increased systemic exposure of selegiline and its metabolites, L-amphetamine and L-methamphetamine were seen after single application of EMSAM 6 mg per 24 hours in subjects who had received carbamazepine (400 mg per day) for 14 days. Changes in plasma selegiline concentrations were nearly 2-fold and variable across the subject population. Such increases may increase the risk of a hypertensive crisis when carbamazepine is used with EMSAM at any dose [see Contraindications (4), Warnings and Precautions (5.3) and Drug Interaction (7.4)].","ncit:positive","ncit:quantitative","carbamazepine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","400","selegiline","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","6","SD","Oral","1","Daily","Oral","14","Unk","2","Fold","Increase","Unk","UNK","UNK","2","Fold","Increase","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html","2015-09-03 15:45:10 -0400","DDI-clinical-trial","evidence-supports","Alprazolam    In subjects who had received EMSAM 6 mg per 24 hours for 7 days, co-administration with alprazolam (15 mg per day), a CYP3A4 and CYP3A5 substrate, did not affect the pharmacokinetics of alprazolam or selegiline [see Drug Interactions (7.4) and (7.5)]. ","ncit:negative","ncit:quantitative","EMSAM","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:object-drug-of-interaction","6","alprazolam","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","15","Daily","Oral","7","Daily","Oral","7","Unk","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html","2015-09-03 15:43:15 -0400","drug-drug-interaction","evidence-supports","Carbamazepine is contraindicated with MAOIs, including selegiline [see Contraindications (4), Warnings and Precautions (5.3) and Clinical Pharmacology (12.3)]. ","ncit:positive","ncit:Qualitative","selegiline","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,"Carbamazepine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html","2015-09-03 15:43:15 -0400","drug-drug-interaction","evidence-supports","No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. ","ncit:negative","ncit:Qualitative","EMSAM","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:precipitant-drug-of-interaction",,"ketoconazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html","2015-09-03 15:42:22 -0400","drug-drug-interaction","evidence-supports","No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. ","ncit:negative","ncit:Qualitative","EMSAM","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:precipitant-drug-of-interaction",,"levothyroxine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html","2015-09-03 15:42:22 -0400","drug-drug-interaction","evidence-supports","No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperdione, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM. EMSAM had no clinically relevant effect on pharmacokinetics of these drugs.","ncit:negative","ncit:Qualitative","EMSAM","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:precipitant-drug-of-interaction",,"olanzapine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html","2015-09-03 15:42:22 -0400","drug-drug-interaction","evidence-supports","No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. ","ncit:negative","ncit:Qualitative","EMSAM","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:precipitant-drug-of-interaction",,"risperidone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html","2015-09-03 15:42:22 -0400","drug-drug-interaction","evidence-supports","No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperdione, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM. EMSAM had no clinically relevant effect on pharmacokinetics of these drugs.","ncit:negative","ncit:Qualitative","EMSAM","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:precipitant-drug-of-interaction",,"warfarin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html","2015-09-03 15:42:22 -0400","drug-drug-interaction","evidence-supports","No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperdione, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM. EMSAM had no clinically relevant effect on pharmacokinetics of these drugs. ","ncit:negative","ncit:Qualitative","alprazolam","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,"EMSAM","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html","2015-09-03 15:42:22 -0400","drug-drug-interaction","evidence-supports","No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperdione, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM. EMSAM had no clinically relevant effect on pharmacokinetics of these drugs.","ncit:negative","ncit:Qualitative","ibuprofen","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,"EMSAM","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html","2015-09-03 15:42:22 -0400","drug-drug-interaction","evidence-supports","No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. ","ncit:negative","ncit:Qualitative","EMSAM","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:precipitant-drug-of-interaction",,"alprazolam","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html","2015-09-03 15:42:22 -0400","drug-drug-interaction","evidence-supports","No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperdione, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM. EMSAM had no clinically relevant effect on pharmacokinetics of these drugs.","ncit:negative","ncit:Qualitative","EMSAM","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:precipitant-drug-of-interaction",,"risperdione","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html","2015-09-03 15:42:22 -0400","drug-drug-interaction","evidence-supports","No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. ","ncit:negative","ncit:Qualitative","EMSAM","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:precipitant-drug-of-interaction",,"ibuprofen","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html","2015-09-03 15:42:22 -0400","drug-drug-interaction","evidence-supports","No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. ","ncit:negative","ncit:Qualitative","EMSAM","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:precipitant-drug-of-interaction",,"olanzapine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html","2015-09-03 15:42:22 -0400","drug-drug-interaction","evidence-supports","No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperdione, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM. EMSAM had no clinically relevant effect on pharmacokinetics of these drugs.","ncit:negative","ncit:Qualitative","levothyroxine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,"EMSAM","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/cc9e1c8c-0e2b-44e2-878b-27057f786be9.html","2015-08-20 13:57:35 -0400","drug-drug-interaction","evidence-supports","Experience with GILENYA in patients receiving concurrent therapy with drugs that slow the heart rate or atrioventricular conduction (e.g., beta blockers, digoxin, or heart rate-slowing calcium channel blockers such as diltiazem or verapamil) is limited. Because initiation of GILENYA treatment may result in an additional decrease in heart rate, concomitant use of these drugs during GILENYA initiation may be associated with severe bradycardia or heart block. Seek advice from the prescribing physician regarding the possibility to switch to drugs that do not slow the heart rate or atrioventricular conduction before initiating GILENYA. Patients who cannot switch, should have overnight continuous ECG monitoring after the first dose [see Dosage and Administration (2) and Warnings and Precautions (5.1)]","ncit:positive","ncit:Qualitative","calcium channel blockers","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:object-drug-of-interaction",,"GILENYA","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/cc9e1c8c-0e2b-44e2-878b-27057f786be9.html","2015-08-20 13:57:35 -0400","drug-drug-interaction","evidence-supports","Experience with GILENYA in patients receiving concurrent therapy with drugs that slow the heart rate or atrioventricular conduction (e.g., beta blockers, digoxin, or heart rate-slowing calcium channel blockers such as diltiazem or verapamil) is limited. Because initiation of GILENYA treatment may result in an additional decrease in heart rate, concomitant use of these drugs during GILENYA initiation may be associated with severe bradycardia or heart block. Seek advice from the prescribing physician regarding the possibility to switch to drugs that do not slow the heart rate or atrioventricular conduction before initiating GILENYA. Patients who cannot switch, should have overnight continuous ECG monitoring after the first dose [see Dosage and Administration (2) and Warnings and Precautions (5.1)].","ncit:positive","ncit:Qualitative","GILENYA","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:precipitant-drug-of-interaction",,"verapamil","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/cc9e1c8c-0e2b-44e2-878b-27057f786be9.html","2015-08-20 13:57:35 -0400","drug-drug-interaction","evidence-supports","Antineoplastic, immune-modulating, or immunosuppressive therapies, (including corticosteroids) are expected to increase the risk of immunosuppression, and the risk of additive immune system effects must be considered if these therapies are coadministered with GILENYA. When switching from drugs with prolonged immune effects, such as natalizumab, teriflunomide or mitoxantrone, the duration and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects when initiating GILENYA [see Warnings and Precautions (5.2)].","ncit:positive","ncit:Qualitative","natalizumab","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,"GILENYA","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/cc9e1c8c-0e2b-44e2-878b-27057f786be9.html","2015-08-20 13:57:35 -0400","drug-drug-interaction","evidence-supports","Antineoplastic, immune-modulating, or immunosuppressive therapies, (including corticosteroids) are expected to increase the risk of immunosuppression, and the risk of additive immune system effects must be considered if these therapies are coadministered with GILENYA. When switching from drugs with prolonged immune effects, such as natalizumab, teriflunomide or mitoxantrone, the duration and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects when initiating GILENYA [see Warnings and Precautions (5.2)].","ncit:positive","ncit:Qualitative","GILENYA","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:precipitant-drug-of-interaction",,"teriflunomide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/cc9e1c8c-0e2b-44e2-878b-27057f786be9.html","2015-08-20 13:57:35 -0400","drug-drug-interaction","evidence-supports","Experience with GILENYA in patients receiving concurrent therapy with drugs that slow the heart rate or atrioventricular conduction (e.g., beta blockers, digoxin, or heart rate-slowing calcium channel blockers such as diltiazem or verapamil) is limited. Because initiation of GILENYA treatment may result in an additional decrease in heart rate, concomitant use of these drugs during GILENYA initiation may be associated with severe bradycardia or heart block. Seek advice from the prescribing physician regarding the possibility to switch to drugs that do not slow the heart rate or atrioventricular conduction before initiating GILENYA. Patients who cannot switch, should have overnight continuous ECG monitoring after the first dose [see Dosage and Administration (2) and Warnings and Precautions (5.1)]","ncit:positive","ncit:Qualitative","beta blockers","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group","dikbD2R:object-drug-of-interaction",,"GILENYA","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/cc9e1c8c-0e2b-44e2-878b-27057f786be9.html","2015-08-20 13:57:35 -0400","drug-drug-interaction","evidence-supports","Experience with GILENYA in patients receiving concurrent therapy with drugs that slow the heart rate or atrioventricular conduction (e.g., beta blockers, digoxin, or heart rate-slowing calcium channel blockers such as diltiazem or verapamil) is limited. Because initiation of GILENYA treatment may result in an additional decrease in heart rate, concomitant use of these drugs during GILENYA initiation may be associated with severe bradycardia or heart block. Seek advice from the prescribing physician regarding the possibility to switch to drugs that do not slow the heart rate or atrioventricular conduction before initiating GILENYA. Patients who cannot switch, should have overnight continuous ECG monitoring after the first dose [see Dosage and Administration (2) and Warnings and Precautions (5.1)].","ncit:positive","ncit:Qualitative","GILENYA","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:precipitant-drug-of-interaction",,"digoxin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/cc9e1c8c-0e2b-44e2-878b-27057f786be9.html","2015-08-20 13:57:35 -0400","drug-drug-interaction","evidence-supports","Antineoplastic, immune-modulating, or immunosuppressive therapies, (including corticosteroids) are expected to increase the risk of immunosuppression, and the risk of additive immune system effects must be considered if these therapies are coadministered with GILENYA. When switching from drugs with prolonged immune effects, such as natalizumab, teriflunomide or mitoxantrone, the duration and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects when initiating GILENYA [see Warnings and Precautions (5.2)].","ncit:positive","ncit:Qualitative","GILENYA","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:precipitant-drug-of-interaction",,"mitoxantrone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/cc9e1c8c-0e2b-44e2-878b-27057f786be9.html","2015-08-20 13:57:35 -0400","drug-drug-interaction","evidence-supports","Experience with GILENYA in patients receiving concurrent therapy with drugs that slow the heart rate or atrioventricular conduction (e.g., beta blockers, digoxin, or heart rate-slowing calcium channel blockers such as diltiazem or verapamil) is limited. Because initiation of GILENYA treatment may result in an additional decrease in heart rate, concomitant use of these drugs during GILENYA initiation may be associated with severe bradycardia or heart block. Seek advice from the prescribing physician regarding the possibility to switch to drugs that do not slow the heart rate or atrioventricular conduction before initiating GILENYA. Patients who cannot switch, should have overnight continuous ECG monitoring after the first dose [see Dosage and Administration (2) and Warnings and Precautions (5.1)].","ncit:positive","ncit:Qualitative","GILENYA","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:precipitant-drug-of-interaction",,"diltiazem","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/cc9e1c8c-0e2b-44e2-878b-27057f786be9.html","2015-08-20 13:53:28 -0400","DDI-clinical-trial","evidence-supports","The blood levels of fingolimod and fingolimod-phosphate are increased by 1.7-fold when used concomitantly with ketoconazole. Patients who use GILENYA and systemic ketoconazole concomitantly should be closely monitored, as the risk of adverse reactions is greater.","ncit:positive","ncit:quantitative","ketoconazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","Unk","fingolimod","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","Unk","UNK","UNK","Unk","UNK","UNK","Unk","Unk","1.7","Fold","Increase","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html","2015-08-20 13:06:41 -0400","DDI-clinical-trial","evidence-supports","There was an increase in mean ethinylestradiol Cmax and AUC0–24 (1.58- and 1.54-fold, respectively) and levonorgestrel Cmax and AUC0–24 (1.33- and 1.41-fold, respectively) following repeated doses of teriflunomide [see Drug Interactions (7)].","ncit:positive","ncit:quantitative","levonorgestrel","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","Unk","teriflunomide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","Unk","UNK","UNK","Unk","UNK","UNK","Unk","Unk","1.41","Fold","Increase","Unk","UNK","UNK","1.33","Fold","Increase","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html","2015-08-20 13:06:41 -0400","DDI-clinical-trial","evidence-supports","There was an increase in mean repaglinide Cmax and AUC (1.7- and 2.4-fold, respectively), following repeated doses of teriflunomide and a single dose of 0.25 mg repaglinide, suggesting that teriflunomide is an inhibitor of CYP2C8 in vivo. The magnitude of interaction could be higher at the recommended repaglinide dose [see Drug Interactions (7)].","ncit:positive","ncit:quantitative","repaglinide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","Unk","teriflunomide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","0.25","SD","UNK","1","UNK","UNK","Unk","Unk","2.4","Fold","Increase","Unk","UNK","UNK","1.7","Fold","Increase","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html","2015-08-20 13:06:41 -0400","drug-drug-interaction","evidence-supports","Potent CYP and transporter inducers: Rifampin did not affect the pharmacokinetics of teriflunomide.","ncit:negative","ncit:Qualitative","teriflunomide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,"Rifampin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html","2015-08-20 13:06:41 -0400","DDI-clinical-trial","evidence-supports","Repeated doses of teriflunomide decreased mean Cmax and AUC of caffeine by 18% and 55%, respectively, suggesting that teriflunomide may be a weak inducer of CYP1A2 in vivo.","ncit:positive","ncit:quantitative","caffeine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","Unk","teriflunomide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","Unk","UNK","UNK","Unk","UNK","UNK","Unk","Unk","55","Percent","Increase","Unk","UNK","UNK","18","Percent","Increase","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html","2015-08-20 13:06:41 -0400","DDI-clinical-trial","evidence-supports","There was an increase in mean ethinylestradiol Cmax and AUC0–24 (1.58- and 1.54-fold, respectively) and levonorgestrel Cmax and AUC0–24 (1.33- and 1.41-fold, respectively) following repeated doses of teriflunomide [see Drug Interactions (7)].","ncit:positive","ncit:quantitative","ethinylestradiol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","Unk","teriflunomide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","Unk","UNK","UNK","Unk","UNK","UNK","Unk","Unk","1.54","Fold","Increase","Unk","UNK","UNK","1.58","Fold","Increase","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html","2015-08-20 13:06:41 -0400","drug-drug-interaction","evidence-supports","Teriflunomide did not affect the pharmacokinetics of bupropion (a CYP2B6 substrate), midazolam (a CYP3A4 substrate), S-warfarin (a CYP2C9 substrate), omeprazole (a CYP2C19 substrate), and metoprolol (a CYP2D6 substrate).","ncit:negative","ncit:Qualitative","Teriflunomide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"warfarin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html","2015-08-20 13:06:41 -0400","drug-drug-interaction","evidence-supports","Teriflunomide did not affect the pharmacokinetics of bupropion (a CYP2B6 substrate), midazolam (a CYP3A4 substrate), S-warfarin (a CYP2C9 substrate), omeprazole (a CYP2C19 substrate), and metoprolol (a CYP2D6 substrate).","ncit:negative","ncit:Qualitative","Teriflunomide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"bupropion","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html","2015-08-20 13:06:41 -0400","drug-drug-interaction","evidence-supports","Teriflunomide did not affect the pharmacokinetics of bupropion (a CYP2B6 substrate), midazolam (a CYP3A4 substrate), S-warfarin (a CYP2C9 substrate), omeprazole (a CYP2C19 substrate), and metoprolol (a CYP2D6 substrate).","ncit:negative","ncit:Qualitative","Teriflunomide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"omeprazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html","2015-08-20 13:06:41 -0400","drug-drug-interaction","evidence-supports","Teriflunomide did not affect the pharmacokinetics of bupropion (a CYP2B6 substrate), midazolam (a CYP3A4 substrate), S-warfarin (a CYP2C9 substrate), omeprazole (a CYP2C19 substrate), and metoprolol (a CYP2D6 substrate).","ncit:negative","ncit:Qualitative","Teriflunomide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"metoprolol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html","2015-08-20 13:06:41 -0400","drug-drug-interaction","evidence-supports","Teriflunomide did not affect the pharmacokinetics of bupropion (a CYP2B6 substrate), midazolam (a CYP3A4 substrate), S-warfarin (a CYP2C9 substrate), omeprazole (a CYP2C19 substrate), and metoprolol (a CYP2D6 substrate).","ncit:negative","ncit:Qualitative","Teriflunomide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"midazolam","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html","2015-08-20 13:06:41 -0400","DDI-clinical-trial","evidence-supports","There was an increase in mean rosuvastatin Cmax and AUC (2.65- and 2.51-fold, respectively), following repeated doses of teriflunomide , suggesting that teriflunomide is an inhibitor of BCRP transporter and organic anion transporting polypeptide 1B1 and 1B3 (OATP1B1/1B3) [see Drug Interactions (7)].","ncit:positive","ncit:quantitative","rosuvastatin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","Unk","teriflunomide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","Unk","UNK","UNK","Unk","UNK","UNK","Unk","Unk","2.51","Fold","Increase","Unk","UNK","UNK","2.65","Fold","Increase","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html","2015-08-20 13:06:41 -0400","DDI-clinical-trial","evidence-supports","There was an increase in mean cefaclor Cmax and AUC (1.43- and 1.54-fold, respectively), following repeated doses of teriflunomide, suggesting that teriflunomide is an inhibitor of organic anion transporter 3 (OAT3) in vivo [see Drug Interactions (7)].","ncit:positive","ncit:quantitative","cefaclor","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","Unk","teriflunomide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","Unk","UNK","UNK","Unk","UNK","UNK","Unk","Unk","1.54","Fold","Increase","Unk","UNK","UNK","1.43","Fold","Increase","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html","2015-08-20 12:53:42 -0400","drug-drug-interaction","evidence-supports","Teriflunomide inhibits the activity of BCRP and OATP1B1/1B3 in vivo. For a patient taking AUBAGIO, the dose of rosuvastatin should not exceed 10 mg once daily. For other substrates of BCRP (e.g., mitoxantrone) and drugs in the OATP family (e.g., methotrexate, rifampin), especially HMG-Co reductase inhibitors (e.g., atorvastatin, nateglinide, pravastatin, repaglinide, and simvastatin), consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of increased exposures to the drugs while patients are taking AUBAGIO [see Clinical Pharmacology (12.3)]","ncit:positive","ncit:Qualitative","Teriflunomide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"rosuvastatin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html","2015-08-20 12:50:04 -0400","drug-drug-interaction","evidence-supports","Teriflunomide inhibits the activity of BCRP and OATP1B1/1B3 in vivo. For a patient taking AUBAGIO, the dose of rosuvastatin should not exceed 10 mg once daily. For other substrates of BCRP (e.g., mitoxantrone) and drugs in the OATP family (e.g., methotrexate, rifampin), especially HMG-Co reductase inhibitors (e.g., atorvastatin, nateglinide, pravastatin, repaglinide, and simvastatin), consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of increased exposures to the drugs while patients are taking AUBAGIO [see Clinical Pharmacology (12.3)].","ncit:positive","ncit:Qualitative","mitoxantrone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,"Teriflunomide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html","2015-08-20 12:50:04 -0400","drug-drug-interaction","evidence-supports","Teriflunomide inhibits the activity of BCRP and OATP1B1/1B3 in vivo. For a patient taking AUBAGIO, the dose of rosuvastatin should not exceed 10 mg once daily. For other substrates of BCRP (e.g., mitoxantrone) and drugs in the OATP family (e.g., methotrexate, rifampin), especially HMG-Co reductase inhibitors (e.g., atorvastatin, nateglinide, pravastatin, repaglinide, and simvastatin), consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of increased exposures to the drugs while patients are taking AUBAGIO [see Clinical Pharmacology (12.3)].","ncit:positive","ncit:Qualitative","Teriflunomide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"simvastatin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html","2015-08-20 12:50:04 -0400","drug-drug-interaction","evidence-supports","Teriflunomide inhibits the activity of BCRP and OATP1B1/1B3 in vivo. For a patient taking AUBAGIO, the dose of rosuvastatin should not exceed 10 mg once daily. For other substrates of BCRP (e.g., mitoxantrone) and drugs in the OATP family (e.g., methotrexate, rifampin), especially HMG-Co reductase inhibitors (e.g., atorvastatin, nateglinide, pravastatin, repaglinide, and simvastatin), consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of increased exposures to the drugs while patients are taking AUBAGIO [see Clinical Pharmacology (12.3)]","ncit:positive","ncit:Qualitative","pravastatin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,"Teriflunomide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html","2015-08-20 12:50:04 -0400","drug-drug-interaction","evidence-supports","Teriflunomide inhibits the activity of BCRP and OATP1B1/1B3 in vivo. For a patient taking AUBAGIO, the dose of rosuvastatin should not exceed 10 mg once daily. For other substrates of BCRP (e.g., mitoxantrone) and drugs in the OATP family (e.g., methotrexate, rifampin), especially HMG-Co reductase inhibitors (e.g., atorvastatin, nateglinide, pravastatin, repaglinide, and simvastatin), consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of increased exposures to the drugs while patients are taking AUBAGIO [see Clinical Pharmacology (12.3)]","ncit:positive","ncit:Qualitative","Teriflunomide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"repaglinide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html","2015-08-20 12:50:04 -0400","drug-drug-interaction","evidence-supports","Teriflunomide inhibits the activity of BCRP and OATP1B1/1B3 in vivo. For a patient taking AUBAGIO, the dose of rosuvastatin should not exceed 10 mg once daily. For other substrates of BCRP (e.g., mitoxantrone) and drugs in the OATP family (e.g., methotrexate, rifampin), especially HMG-Co reductase inhibitors (e.g., atorvastatin, nateglinide, pravastatin, repaglinide, and simvastatin), consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of increased exposures to the drugs while patients are taking AUBAGIO [see Clinical Pharmacology (12.3)]","ncit:positive","ncit:Qualitative","Teriflunomide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"methotrexate","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html","2015-08-20 12:50:04 -0400","drug-drug-interaction","evidence-supports","Teriflunomide inhibits the activity of BCRP and OATP1B1/1B3 in vivo. For a patient taking AUBAGIO, the dose of rosuvastatin should not exceed 10 mg once daily. For other substrates of BCRP (e.g., mitoxantrone) and drugs in the OATP family (e.g., methotrexate, rifampin), especially HMG-Co reductase inhibitors (e.g., atorvastatin, nateglinide, pravastatin, repaglinide, and simvastatin), consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of increased exposures to the drugs while patients are taking AUBAGIO [see Clinical Pharmacology (12.3)].","ncit:positive","ncit:Qualitative","nateglinide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,"Teriflunomide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html","2015-08-20 12:50:04 -0400","drug-drug-interaction","evidence-supports","Teriflunomide inhibits the activity of BCRP and OATP1B1/1B3 in vivo. For a patient taking AUBAGIO, the dose of rosuvastatin should not exceed 10 mg once daily. For other substrates of BCRP (e.g., mitoxantrone) and drugs in the OATP family (e.g., methotrexate, rifampin), especially HMG-Co reductase inhibitors (e.g., atorvastatin, nateglinide, pravastatin, repaglinide, and simvastatin), consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of increased exposures to the drugs while patients are taking AUBAGIO [see Clinical Pharmacology (12.3)].","ncit:positive","ncit:Qualitative","Teriflunomide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"atorvastatin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html","2015-08-20 12:50:04 -0400","drug-drug-interaction","evidence-supports","Teriflunomide inhibits the activity of BCRP and OATP1B1/1B3 in vivo. For a patient taking AUBAGIO, the dose of rosuvastatin should not exceed 10 mg once daily. For other substrates of BCRP (e.g., mitoxantrone) and drugs in the OATP family (e.g., methotrexate, rifampin), especially HMG-Co reductase inhibitors (e.g., atorvastatin, nateglinide, pravastatin, repaglinide, and simvastatin), consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of increased exposures to the drugs while patients are taking AUBAGIO [see Clinical Pharmacology (12.3)].","ncit:positive","ncit:Qualitative","Teriflunomide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"rosuvastatin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html","2015-08-20 12:50:04 -0400","drug-drug-interaction","evidence-supports","Teriflunomide inhibits the activity of BCRP and OATP1B1/1B3 in vivo. For a patient taking AUBAGIO, the dose of rosuvastatin should not exceed 10 mg once daily. For other substrates of BCRP (e.g., mitoxantrone) and drugs in the OATP family (e.g., methotrexate, rifampin), especially HMG-Co reductase inhibitors (e.g., atorvastatin, nateglinide, pravastatin, repaglinide, and simvastatin), consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of increased exposures to the drugs while patients are taking AUBAGIO [see Clinical Pharmacology (12.3)].","ncit:positive","ncit:Qualitative","Teriflunomide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"rifampin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html","2015-08-20 11:48:50 -0400","drug-drug-interaction","evidence-supports","Teriflunomide inhibits the activity of OAT3 in vivo. In patients taking AUBAGIO, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased. Monitor these patients and adjust the dose of the concomitant drug(s) which are OAT3 substrates as required [see Clinical Pharmacology (12.3)].","ncit:positive","ncit:Qualitative","penicillin G","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,"Teriflunomide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html","2015-08-20 11:48:50 -0400","drug-drug-interaction","evidence-supports","Teriflunomide inhibits the activity of OAT3 in vivo. In patients taking AUBAGIO, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased. Monitor these patients and adjust the dose of the concomitant drug(s) which are OAT3 substrates as required [see Clinical Pharmacology (12.3)].","ncit:positive","ncit:Qualitative","methotrexate","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,"Teriflunomide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html","2015-08-20 11:48:50 -0400","drug-drug-interaction","evidence-supports","Teriflunomide inhibits the activity of OAT3 in vivo. In patients taking AUBAGIO, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased. Monitor these patients and adjust the dose of the concomitant drug(s) which are OAT3 substrates as required [see Clinical Pharmacology (12.3)].","ncit:positive","ncit:Qualitative","Teriflunomide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"cimetidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html","2015-08-20 11:48:50 -0400","drug-drug-interaction","evidence-supports","Teriflunomide inhibits the activity of OAT3 in vivo. In patients taking AUBAGIO, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased. Monitor these patients and adjust the dose of the concomitant drug(s) which are OAT3 substrates as required [see Clinical Pharmacology (12.3)].","ncit:positive","ncit:Qualitative","Teriflunomide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"cefaclor","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html","2015-08-20 11:48:50 -0400","drug-drug-interaction","evidence-supports","Teriflunomide inhibits the activity of OAT3 in vivo. In patients taking AUBAGIO, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased. Monitor these patients and adjust the dose of the concomitant drug(s) which are OAT3 substrates as required [see Clinical Pharmacology (12.3)].","ncit:positive","ncit:Qualitative","zidovudine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,"Teriflunomide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html","2015-08-20 11:48:50 -0400","drug-drug-interaction","evidence-supports","Teriflunomide inhibits the activity of OAT3 in vivo. In patients taking AUBAGIO, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased. Monitor these patients and adjust the dose of the concomitant drug(s) which are OAT3 substrates as required [see Clinical Pharmacology (12.3)].","ncit:positive","ncit:Qualitative","Teriflunomide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"ketoprofen","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html","2015-08-20 11:48:50 -0400","drug-drug-interaction","evidence-supports","Teriflunomide inhibits the activity of OAT3 in vivo. In patients taking AUBAGIO, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased. Monitor these patients and adjust the dose of the concomitant drug(s) which are OAT3 substrates as required [see Clinical Pharmacology (12.3)].","ncit:positive","ncit:Qualitative","furosemide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,"Teriflunomide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html","2015-08-20 11:48:50 -0400","drug-drug-interaction","evidence-supports","Teriflunomide inhibits the activity of OAT3 in vivo. In patients taking AUBAGIO, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased. Monitor these patients and adjust the dose of the concomitant drug(s) which are OAT3 substrates as required [see Clinical Pharmacology (12.3)].","ncit:positive","ncit:Qualitative","Teriflunomide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"ciprofloxacin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html","2015-08-20 11:43:54 -0400","drug-drug-interaction","evidence-supports","AUBAGIO may increase the systemic exposures of ethinylestradiol and levonorgestrel. Consideration should be given to the type or dose of contraceptives used in combination with AUBAGIO [see Clinical Pharmacology (12.3)].","ncit:positive","ncit:Qualitative","ethinylestradiol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,"AUBAGIO","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html","2015-08-20 11:43:54 -0400","drug-drug-interaction","evidence-supports","Teriflunomide may be a weak inducer of CYP1A2 in vivo. In patients taking AUBAGIO, exposure of drugs metabolized by CYP1A2 (e.g., alosetron, duloxetine, theophylline, tizanidine) may be reduced. Monitor these patients and adjust the dose of the concomitant drug(s) metabolized by CYP1A2 as required [see Clinical Pharmacology (12.3)]","ncit:positive","ncit:Qualitative","Teriflunomide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"tizanidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html","2015-08-20 11:43:54 -0400","drug-drug-interaction","evidence-supports","Teriflunomide may be a weak inducer of CYP1A2 in vivo. In patients taking AUBAGIO, exposure of drugs metabolized by CYP1A2 (e.g., alosetron, duloxetine, theophylline, tizanidine) may be reduced. Monitor these patients and adjust the dose of the concomitant drug(s) metabolized by CYP1A2 as required [see Clinical Pharmacology (12.3)].","ncit:positive","ncit:Qualitative","alosetron","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,"Teriflunomide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html","2015-08-20 11:43:54 -0400","drug-drug-interaction","evidence-supports","Teriflunomide may be a weak inducer of CYP1A2 in vivo. In patients taking AUBAGIO, exposure of drugs metabolized by CYP1A2 (e.g., alosetron, duloxetine, theophylline, tizanidine) may be reduced. Monitor these patients and adjust the dose of the concomitant drug(s) metabolized by CYP1A2 as required [see Clinical Pharmacology (12.3)].","ncit:positive","ncit:Qualitative","theophylline","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,"Teriflunomide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html","2015-08-20 11:43:54 -0400","drug-drug-interaction","evidence-supports","Teriflunomide may be a weak inducer of CYP1A2 in vivo. In patients taking AUBAGIO, exposure of drugs metabolized by CYP1A2 (e.g., alosetron, duloxetine, theophylline, tizanidine) may be reduced. Monitor these patients and adjust the dose of the concomitant drug(s) metabolized by CYP1A2 as required [see Clinical Pharmacology (12.3)].","ncit:positive","ncit:Qualitative","duloxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,"Teriflunomide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html","2015-08-20 11:38:24 -0400","drug-drug-interaction","evidence-supports","Teriflunomide is an inhibitor of CYP2C8 in vivo. In patients taking AUBAGIO, exposure of drugs metabolized by CYP2C8 (e.g., paclitaxel, pioglitazone, repaglinide, rosiglitazone) may be increased. Monitor these patients and adjust the dose of the concomitant drug(s) metabolized by CYP2C8 as required [see Clinical Pharmacology (12.3)].","ncit:positive","ncit:Qualitative","rosiglitazone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,"Teriflunomide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html","2015-08-20 11:38:24 -0400","drug-drug-interaction","evidence-supports","Teriflunomide is an inhibitor of CYP2C8 in vivo. In patients taking AUBAGIO, exposure of drugs metabolized by CYP2C8 (e.g., paclitaxel, pioglitazone, repaglinide, rosiglitazone) may be increased. Monitor these patients and adjust the dose of the concomitant drug(s) metabolized by CYP2C8 as required [see Clinical Pharmacology (12.3)].","ncit:positive","ncit:Qualitative","paclitaxel","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,"Teriflunomide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html","2015-08-20 11:38:24 -0400","drug-drug-interaction","evidence-supports","AUBAGIO may increase the systemic exposures of ethinylestradiol and levonorgestrel. Consideration should be given to the type or dose of contraceptives used in combination with AUBAGIO [see Clinical Pharmacology (12.3)].","ncit:positive","ncit:Qualitative","AUBAGIO","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"levonorgestrel","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html","2015-08-20 11:38:24 -0400","drug-drug-interaction","evidence-supports","Teriflunomide is an inhibitor of CYP2C8 in vivo. In patients taking AUBAGIO, exposure of drugs metabolized by CYP2C8 (e.g., paclitaxel, pioglitazone, repaglinide, rosiglitazone) may be increased. Monitor these patients and adjust the dose of the concomitant drug(s) metabolized by CYP2C8 as required [see Clinical Pharmacology (12.3)].","ncit:positive","ncit:Qualitative","pioglitazone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,"Teriflunomide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html","2015-08-20 11:38:24 -0400","drug-drug-interaction","evidence-supports","Teriflunomide is an inhibitor of CYP2C8 in vivo. In patients taking AUBAGIO, exposure of drugs metabolized by CYP2C8 (e.g., paclitaxel, pioglitazone, repaglinide, rosiglitazone) may be increased. Monitor these patients and adjust the dose of the concomitant drug(s) metabolized by CYP2C8 as required [see Clinical Pharmacology (12.3)].","ncit:positive","ncit:Qualitative","repaglinide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,"Teriflunomide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e338e89-3cf2-48eb-b6e2-a06c608c6513.html","2015-08-20 11:32:27 -0400","DDI-clinical-trial","evidence-supports","In a CYP2C8 drug-drug interaction trial in healthy subjects, the AUC of pioglitazone was increased by 46% when pioglitazone was given together with a single dose of 1,000 mg abiraterone acetate [see Drug Interactions (7.2)].","ncit:positive","ncit:quantitative","pioglitazone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","1000","abiraterone acetate","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","Unk","UNK","UNK","Unk","SD","UNK","1","Unk","46","Percent","Increase","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e338e89-3cf2-48eb-b6e2-a06c608c6513.html","2015-08-20 11:32:27 -0400","drug-drug-interaction","evidence-supports","In a separate clinical pharmacokinetic interaction study of healthy subjects, co-administration of ketoconazole, a strong inhibitor of CYP3A4, had no clinically meaningful effect on the pharmacokinetics of abiraterone [see Drug Interactions (7.1)].","ncit:negative","ncit:Qualitative","ketoconazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"abiraterone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e338e89-3cf2-48eb-b6e2-a06c608c6513.html","2015-08-20 11:30:25 -0400","DDI-clinical-trial","evidence-supports","Abiraterone is a substrate of CYP3A4, in vitro. In a clinical pharmacokinetic interaction study of healthy subjects pretreated with a strong CYP3A4 inducer (rifampin, 600 mg daily for 6 days) followed by a single dose of abiraterone acetate 1,000 mg, the mean plasma AUC∞ of abiraterone was decreased by 55% [see Drug Interactions (7.1)].","ncit:positive","ncit:quantitative","abiraterone acetate","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","600","rifampin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","1000","SD","UNK","1","Daily","UNK","6","Unk","55","Percent","Decrease","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e338e89-3cf2-48eb-b6e2-a06c608c6513.html","2015-08-20 11:30:25 -0400","DDI-clinical-trial","evidence-supports","In a clinical study to determine the effects of abiraterone acetate 1,000 mg daily (plus prednisone 5 mg twice daily) on a single 100 mg dose of the CYP1A2 substrate theophylline, no increase in systemic exposure of theophylline was observed.","ncit:negative","ncit:quantitative","theophylline","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","1000","abiraterone acetate","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","100","SD","UNK","1","Daily","UNK","Unk","Unk","0","Percent","Increase","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e338e89-3cf2-48eb-b6e2-a06c608c6513.html","2015-08-20 11:17:13 -0400","DDI-clinical-trial","evidence-supports","In an in vivo drug-drug interaction trial, the Cmax and AUC of dextromethorphan (CYP2D6 substrate) were increased 2.8- and 2.9-fold, respectively when dextromethorphan 30 mg was given with abiraterone acetate 1,000 mg daily (plus prednisone 5 mg twice daily). The AUC for dextrorphan, the active metabolite of dextromethorphan, increased approximately 1.3 fold [see Drug Interactions (7.2)].","ncit:positive","ncit:quantitative","abiraterone acetate","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","Unk","dextrorphan","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite","dikbD2R:object-drug-of-interaction","1000","UNK","UNK","Unk","Daily","UNK","Unk","Unk","1.3","Fold","Increase","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e338e89-3cf2-48eb-b6e2-a06c608c6513.html","2015-08-20 11:17:13 -0400","DDI-clinical-trial","evidence-supports","In an in vivo drug-drug interaction trial, the Cmax and AUC of dextromethorphan (CYP2D6 substrate) were increased 2.8- and 2.9-fold, respectively when dextromethorphan 30 mg was given with abiraterone acetate 1,000 mg daily (plus prednisone 5 mg twice daily). The AUC for dextrorphan, the active metabolite of dextromethorphan, increased approximately 1.3 fold [see Drug Interactions (7.2)].","ncit:positive","ncit:quantitative","dextromethorphan","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","1000","abiraterone acetate","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","30","UNK","UNK","Unk","Daily","UNK","Unk","Unk","2.9","Fold","Increase","Unk","UNK","UNK","2.8","Fold","Increase","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e338e89-3cf2-48eb-b6e2-a06c608c6513.html","2015-08-20 11:10:08 -0400","DDI-clinical-trial","evidence-supports","ZYTIGA is an inhibitor of the hepatic drug-metabolizing enzymes CYP2D6 and CYP2C8. In a CYP2D6 drug-drug interaction trial, the Cmax and AUC of dextromethorphan (CYP2D6 substrate) were increased 2.8- and 2.9-fold, respectively, when dextromethorphan was given with abiraterone acetate 1,000 mg daily and prednisone 5 mg twice daily. Avoid co-administration of abiraterone acetate with substrates of CYP2D6 with a narrow therapeutic index (e.g., thioridazine). If alternative treatments cannot be used, exercise caution and consider a dose reduction of the concomitant CYP2D6 substrate drug [see Clinical Pharmacology (12.3)].","ncit:positive","ncit:quantitative","dextromethorphan","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","1000","abiraterone acetate","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","Unk","UNK","UNK","Unk","Daily","UNK","Unk","Unk","2.9","Fold","Increase","Unk","UNK","UNK","2.8","Fold","Increase","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e338e89-3cf2-48eb-b6e2-a06c608c6513.html","2015-08-20 11:10:08 -0400","DDI-clinical-trial","evidence-supports","In a CYP2C8 drug-drug interaction trial in healthy subjects, the AUC of pioglitazone (CYP2C8 substrate) was increased by 46% when pioglitazone was given together with a single dose of 1,000 mg abiraterone acetate. Therefore, patients should be monitored closely for signs of toxicity related to a CYP2C8 substrate with a narrow therapeutic index if used concomitantly with ZYTIGA [see Clinical Pharmacology (12.3)].","ncit:positive","ncit:quantitative","abiraterone acetate","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","Unk","pioglitazone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","1000","UNK","UNK","Unk","SD","UNK","1","Unk","46","Percent","Increase","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e338e89-3cf2-48eb-b6e2-a06c608c6513.html","2015-08-20 11:10:08 -0400","drug-drug-interaction","evidence-supports","In a dedicated drug interaction trial, co-administration of ketoconazole, a strong inhibitor of CYP3A4, had no clinically meaningful effect on the pharmacokinetics of abiraterone [see Clinical Pharmacology (12.3)].","ncit:negative","ncit:Qualitative","ketoconazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"abiraterone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e338e89-3cf2-48eb-b6e2-a06c608c6513.html","2015-08-20 11:10:08 -0400","DDI-clinical-trial","evidence-supports","Based on in vitro data, ZYTIGA is a substrate of CYP3A4.    In a dedicated drug interaction trial, co-administration of rifampin, a strong CYP3A4 inducer, decreased exposure of abiraterone by 55%. Avoid concomitant strong CYP3A4 inducers during ZYTIGA treatment. If a strong CYP3A4 inducer must be co-administered, increase the ZYTIGA dosing frequency [see Dosage and Administration (2.3) and Clinical Pharmacology (12.3)].","ncit:positive","ncit:quantitative","abiraterone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","Unk","rifampin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","Unk","UNK","UNK","Unk","UNK","UNK","Unk","Unk","55","Percent","Decrease","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/7c295b64-ec39-42ec-9f02-da5b42e775e1.html","2015-08-20 10:29:59 -0400","drug-drug-interaction","evidence-supports","Clinical studies have not shown any drug interactions between bicalutamide and LHRH analogs (goserelin or leuprolide). There is no evidence that bicalutamide induces hepatic enzymes.","ncit:negative","ncit:Qualitative","goserelin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,"bicalutamide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/7c295b64-ec39-42ec-9f02-da5b42e775e1.html","2015-08-20 10:29:59 -0400","DDI-clinical-trial","evidence-supports","In vitro studies have shown that R-bicalutamide is an inhibitor of CYP 3A4 with lesser inhibitory effects on CYP 2C9, 2C19 and 2D6 activity. Clinical studies have shown that with co-administration of bicalutamide, mean midazolam (a CYP 3A4 substrate) levels may be increased 1.5 fold (for Cmax) and 1.9 fold (for AUC). Hence, caution should be exercised when bicalutamide is co-administered with CYP 3A4 substrates.","ncit:positive","ncit:quantitative","midazolam","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","Unk","bicalutamide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","Unk","UNK","UNK","Unk","UNK","UNK","Unk","Unk","1.9","Fold","Increase","Unk","UNK","UNK","1.5","Fold","Increase","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/7c295b64-ec39-42ec-9f02-da5b42e775e1.html","2015-08-20 10:29:59 -0400","drug-drug-interaction","evidence-supports","Clinical studies have not shown any drug interactions between bicalutamide and LHRH analogs (goserelin or leuprolide). There is no evidence that bicalutamide induces hepatic enzymes","ncit:negative","ncit:Qualitative","leuprolide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",,"bicalutamide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
